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ABSTRACT
Placental abruption, one of the most significant causes of perinatal mortality and maternal
morbidity, occurs in 0.5-1% of pregnancies. Its etiology is unknown, but defective trophoblastic
invasion of the spiral arteries and consequent poor vascularization may play a role. The aim of
this study was to define the prepregnancy risk factors of placental abruption, to define the risk
factors during the index pregnancy, and to describe the clinical presentation of placental
abruption. We also wanted to find a biochemical marker for predicting placental abruption early
in pregnancy.
Among women delivering at the University Hospital of Helsinki in 1997-2001 (n=46,742), 198
women with placental abruption and 396 control women were identified. The overall incidence
of placental abruption was 0.42%. The prepregnancy risk factors were smoking (OR 1.7; 95% CI
1.1, 2.7), uterine malformation (OR 8.1; 1.7, 40), previous cesarean section (OR 1.7; 1.1, 2.8),
and history of placental abruption (OR 4.5; 1.1, 18). The risk factors during the index pregnancy
were maternal (adjusted OR 1.8; 95% CI 1.1, 2.9) and paternal smoking (2.2; 1.3, 3.6), use of
alcohol (2.2; 1.1, 4.4), placenta previa (5.7; 1.4, 23.1), preeclampsia (2.7; 1.3, 5.6) and
chorioamnionitis (3.3; 1.0, 10.0). Vaginal bleeding (70%), abdominal pain (51%), bloody
amniotic fluid (50%) and fetal heart rate abnormalities (69%) were the most common clinical
manifestations of placental abruption. Retroplacental blood clot was seen by ultrasound in 15%
of the cases. Neither bleeding nor pain was present in 19% of the cases. Overall, 59% went into
preterm labor (OR 12.9; 95% CI 8.3, 19.8), and 91% were delivered by cesarean section (34.7;
20.0, 60.1). Of the newborns, 25% were growth restricted. The perinatal mortality rate was 9.2%
(OR 10.1; 95% CI 3.4, 30.1).
We then tested selected biochemical markers for prediction of placental abruption. The median
of the maternal serum alpha-fetoprotein (MSAFP) multiples of median (MoM) (1.21) was
significantly higher in the abruption group (n=57) than in the control group (n=108) (1.07)
(p=0.004) at 15-16 gestational weeks. In multivariate analysis, elevated MSAFP remained as an
independent risk factor for placental abruption, adjusting for parity  3, smoking, previous
placental abruption, preeclampsia, bleeding in II or III trimester, and placenta previa. MSAFP 
1.5 MoM had a sensitivity of 29% and a false positive rate of 10%. The levels of the maternal
serum free beta human chorionic gonadotrophin MoM did not differ between the cases and the
controls. None of the angiogenic factors (soluble endoglin, soluble fms-like tyrosine kinase 1, or
placental growth factor) showed any difference between the cases (n=42) and the controls (n=50)
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in the second trimester. The levels of C-reactive protein (CRP) showed no difference between
the cases (n=181) and the controls (n=261) (median 2.35 mg/l [interquartile range {IQR} 1.09-
5.93] versus 2.28 mg/l [IQR 0.92-5.01], not significant) when tested in the first trimester (mean
10.4 gestational weeks). Chlamydia pneumoniae specific immunoglobulin G (IgG) and
immunoglobulin A (IgA) as well as C. trachomatis specific IgG, IgA and chlamydial heat-shock
protein 60 antibody rates were similar between the groups.
In conclusion, although univariate analysis identified many prepregnancy risk factors for
placental abruption, only smoking, uterine malformation, previous cesarean section and history
of placental abruption remained significant by multivariate analysis. During the index pregnancy
maternal alcohol consumption and smoking and smoking by the partner turned out to be the
major independent risk factors for placental abruption. Smoking by both partners multiplied the
risk. The liberal use of ultrasound examination contributed little to the management of women
with placental abruption.
Although second-trimester MSAFP levels were higher in women with subsequent placental
abruption, clinical usefulness of this test is limited due to low sensitivity and high false positive
rate. Similarly, angiogenic factors in early second trimester, or CRP levels, or chlamydial
antibodies in the first trimester failed to predict placental abruption.
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INTRODUCTION
Placental abruption, defined as the complete or partial separation of the placenta before delivery,
is one of the leading causes of vaginal bleeding in the second half of pregnancy (Konje and
Taylor. 2001, Oyelese and Ananth. 2006). Approximately 0.5-1% of the pregnancies are
complicated by placental abruption (Kyrklund-Blomberg et al. 2001, Oyelese and Ananth.
2006). Bleeding and pain are classical symptoms of abruption but the clinical picture of this
emergency varies (Konje and Taylor. 2001, Oyelese and Ananth. 2006). Placental abruption is
one of the most important causes of maternal morbidity and perinatal mortality. Approximately
10% of all preterm births and up to one third of all perinatal deaths are caused by placental
abruption (Ananth et al. 2006a, Oyelese and Ananth. 2006). In many countries the rate of
placental abruption has been increasing (Saftlas et al. 1991, Ananth and Wilcox. 2001), perhaps
due to advancing maternal age and increasing cesarean section rates (Saftlas et al. 1991,
Rasmussen et al. 1996, Ananth et al. 2005).
Although several risk factors are known, the cause of placental abruption often remains
unexplained. The trophoplastic invasion in the spiral arteries and subsequent early
vascularisation may be defective (Dommisse and Tiltman. 1992, Kraus et al. 2004). Moreover,
placental abruption may also be a manifestation of an inflammatory process which could affect
also vascular bed (Ananth et al. 2006b). Despite heightened awareness of placental abruption, it
still remains largely unpredictable and therefore also unpreventable. A reliable biochemical
marker to detect individuals at risk before clinical emergency would be most useful in clinical
practice. Although several markers have been studied (Nolan et al. 1993, Bartha et al. 1997,
Chandra et al. 2003, Florio et al. 2003, Dugoff et al. 2005, Signore et al. 2006), none has so far
emerged as clinically useful.
The present studies were designed to more definitively define prepregnancy risk factors for
placental abruption, to study risk factors of placental abruption during the index pregnancy, and
to describe the clinical presentation of placental abruption. We also wanted to find a new
biochemical marker in order to predict placental abruption in early pregnancy.
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REVIEW OF THE LITERATURE
General aspects
The placenta is a unique organ proving oxygen, nourishment, and protection to the fetus and
having excretory and endocrine functions. After repeated mitotic divisions the zygote transforms
into a blastocyst. The blastomeres of the blastocyst form an outer shell of cells, called
trophoblast and a localized, inner cell mass, the embryoblast. After attaching to the endometrium
the trophoblast cells rapidly proliferate and differentiate into an outer layer of
syncytiotrophoblast and an inner layer of cytotrophoblasts (Faye-Petersen et al. 2006). The
syncytiotrophoblasts form primary, secondary and finally tertiary villi and cytotrophoblasts form
intervillous space. The placenta is fixed to the uterine wall by anchoring villi. By the end of the
fourth month of gestation, the placenta has achieved its definitive form and undergoes no further
anatomic modification. Growth, branching of the villous tree, and formation of fresh villi
continues until term (Fox. 1999).
Implanted placenta naturally separates during the third part of the labor. The separation process
is multiphasic: latent (placental site wall remains thin while placenta-free wall is thick),
contraction (thickening of placental site wall), detachment (actual separation of the placenta
from the adjacent uterine wall), and expulsion (sliding of the placenta out of the uterine cavity).
Uterine contractions cause the separation of the placenta (Herman et al. 2002).
Definition
Placental abruption is classically defined as complete or partial premature separation of a
normally implanted placenta with hemorrhage into the decidua basalis (Konje and Taylor. 2001,
Oyelese and Ananth. 2006). Antepartum hemorrhage, i.e. bleeding after the 20th week of
pregnancy occurs in 2-5% of all pregnancies and placental abruption accounts for approximately
one quarter of such cases (Konje and Taylor. 2001). The diagnosis of placental abruption is
always clinical (Faye-Petersen et al. 2006, Oyelese and Ananth. 2006) and the condition should
be suspected in women who present with vaginal bleeding or abdominal pain or both, a history
of trauma, and in those who present with otherwise unexplained preterm birth (Oyelese and
Ananth. 2006). Symptoms of abruption vary immensely from an asymptomatic form in which
the diagnosis is made only on placental inspection at delivery to massive abruption leading to
fetal death and severe maternal morbidity (Oyelese and Ananth. 2006). The rate of the abruption
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is notably higher (4%) when the diagnosis is made by a pathologist and most of these cases have
an unremarkable obstetric history (Faye-Petersen et al. 2006).
The clinical classification of placental abruption is based on the observation of bleeding at three
principal sites (Figure 1). The bleeding can be subchorionic (between the myometrium and the
placental membranes), retroplacental (between the myometrium and the placenta), or
preplacental (between the placenta and amniotic fluid) (Nyberg et al. 1987). Subchorionic
hematomas may be remote from the placenta but are thought to rise from marginal abruptions.
Preplacental hemorrhage includes both subamniotic hematoma and massive subchorionic
thrombosis (Nyberg et al. 1987, Oyelese and Ananth. 2006). Intraplacental hematoma also
occurs (Kraus et al. 2004). Abruption may be “revealed”, in which cases blood tracks between
the membranes and the decidua escaping through the cervix into the vagina (Oyelese and
Ananth. 2006). This occurs in 65-80% of cases (Konje and Taylor. 2001). The less common
“concealed” abruption occurs when blood accumulates behind the placenta, with no obvious
external bleeding (Oyelese and Ananth. 2006). This happens in 20-35% of cases (Konje and
Taylor. 2001), Figure 2. The concealed type is most dangerous with more severe complications
(Konje and Taylor. 2001). Finally, abruption may be total, involving the entire placenta, in
which case it typically leads to fetal death, or partial with only a portion of the placenta detached





The overall incidence of placental abruption varies from 0.5 to 1.0% (Ananth et al. 1996, Ananth
et al. 1999a, Baumann et al. 2000, Ananth and Wilcox. 2001, Kyrklund-Blomberg et al. 2001).
The rate is lower in case-control (0.35%) than in cohort studies (0.69%) (Ananth et al. 1999a). In
the United States-based studies the incidence has been higher both in cohort (0.81%) and case-
control (0.37%) studies compared with studies conducted outside the U.S. (0.60% and 0.26%,
respectively) (Ananth et al. 1999a). The incidence may vary due to variable diagnostic criteria
(Konje and Taylor. 2001). The incidence is highest at 24-26 weeks of gestation, and drops with
advancing gestation (Rasmussen et al. 1996, Oyelese and Ananth. 2006). However, it occurs
after the 36th week of gestation in about 50% of cases (Konje and Taylor. 2001). Some (Saftlas et
al. 1991, Ananth et al. 2005a, Rasmussen et al. 1996) but not all (Ananth and Cnattingius. 2007)
studies have reported increasing overall rates.
Abruption occurs more frequently in older women, but usually this increase has been attributed
to multiparity ( 3 deliveries), and is independent of age (Baumann et al. 2000, Konje and
Taylor. 2001). However, the literature provides conflicting evidence with respect to whether age
and parity are associated with placental abruption (Kåregård and Gennser. 1986, Krohn et al.
1987, Rasmussen et al. 1996, Kramer et al. 1997, Baumann et al. 2000, Lindqvist and Happach.
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2006). In one study neither parity nor maternal age increased the risk (Krohn et al. 1987). In
another study maternal age > 35 years predicted placental abruption among primiparous but not
among multiparous women (Baumann et al. 2000). In many other studies advanced maternal age
has been an independent risk factor (Rasmussen et al. 1996, Kramer et al. 1997, Lindqvist and
Happach. 2006,). Also mothers less than 20 years of age have been a risk group in some studies
(Kåregård and Gennser. 1986, Saftlas et al. 1991). Being black, unmarried, or of lower
sosioeconomic status are other risk factors for abruption (Krohn et al. 1987, Saftlas et al. 1991,
Kramer et al. 1997, Ananth et al. 1999b).
Maternal consequences
Maternal risks associated with placental abruption depend primarily on the severity of the
abruption (Oyelese and Ananth. 2006). Peripartum risks include obstetric hemorrhage, need for
blood transfusions, hysterectomy, disseminated intravascular coagulopathy (DIC), renal failure
and less commonly, maternal death (Oyelese and Ananth. 2006). Placental abruption attributes to
nearly a quarter of late pregnancy bleeding (Konje and Taylor. 2001). Bleeding can sometimes
lead to maternal hypovolemic shock. Blood loss may be underestimated in placental abruption
because concealed bleeding into the myometrium is difficult to quantify (Konje and Taylor.
2001). The coagulation cascade becomes activated with consumption of coagulation factors and
platelets. Thrombin converts fibrinogen to fibrin, and the stable fibrin clot is the final product of
hemostasis. The fibrinolytic system then breaks down fibrinogen and fibrin. In the presence of
thrombin, activation of the fibrinolytic system generates plasmin, which is responsible for the
lysis of fibrin clots. When the placental detachment is large enough to cause fetal death, the risk
of DIC is high. In this condition, coagulation and fibrinolysis happen without control which
results in simultaneous widespread clotting and bleeding. Placental abruption may also be
associated with acute renal failure resulting from hypovolemia or DIC (Konje and Taylor. 2001).
Maternal mortality decreased from 8% in 1919 to less than 1 % in 1995 (Konje and Taylor.
2001). In the United Kingdom in 2000-2002, four maternal deaths were caused by placental
abruption (Konje and Taylor. 2001). Fetomaternal hemorrhage can lead to severe immunization
in Rhesus-negative patients (Konje and Taylor. 2001).
Women who have had placental abruption are less likely than other women to become pregnant
again (Rasmussen et al. 1997). After placental abruption with survived newborn 59% of women
had subsequently another delivery, compared with 71% of those without abruption. After
perinatal loss corresponding rates were 83% and 85%, respectively (Rasmussen et al. 1997). This
may reflect maternal anxiety and distress caused by placental abruption.
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Having placental abruption has further effects on subsequent maternal health. For instance, the
risk of premature cardiovascular disease is increased by 70% in these women (Ray et al. 2005).
The cause of this is unclear.
Perinatal consequences
Placental abruption is associated with low birth weight, preterm delivery, hypoxia, stillbirth and
perinatal death (Ananth et al. 1999b). Fetal survival depends on the severity of the abruption and
the gestational age (Oyelese and Ananth. 2006). Abruption involving more than 50% of
placental surface is frequently associated with fetal death (Ananth et al. 1999b, Oyelese and
Ananth. 2006). A population based cohort study showed perinatal mortality rate (PNM) of
11.9% among pregnancies complicated by abruption, compared with 0.8% in other births
(Ananth and Wilcox. 2001). The high PNM with abruption can be explained by the strong
association with preterm delivery. However, even term babies with normal birth weight have a
25-fold higher mortality with abruption (Ananth and Wilcox. 2001). Also, the PNM depends to
some extent on neonatal facilities. Over 50% of the perinatal deaths are stillborns (Konje and
Taylor. 2001).
Perinatal mortality is closely related to gestational age. Placental abruption may be implicated in
up to 10% of all preterm births (Ananth et al. 1999b). Although placental abruption is an
important cause of spontaneous preterm birth, it also causes iatrogenic preterm delivery (Ananth
et al. 1999b). In this study the rate for preterm birth among women with placental abruption was
39.6% compared to 9.1% in women without (Ananth et al. 1999b). Approximately 18 % of the
abruptions occur before 32 weeks and 42% occur after 37 weeks (Konje and Taylor. 2001).
Prematurity poses serious threat to the fetus with short-term and long-term neonatal
consequences (Ananth et al. 1999a).
Preterm birth is often associated with birth weight < 2500 g. In one study the rate of giving birth
to a low-birth weight infant among women with placental abruption was 46% compared to 6.4%
among those without (Ananth and Wilcox. 2001). Other consequences include fetal growth
restriction, anemia, and hyperbilirubinemia of the newborn (Hladky et al. 2002).  The association
with fetal growth restriction is so strong that growth restriction alone could be used as a marker
for the risk of abruption (Ananth and Wilcox. 2001). The rate of fetal malformations may be as
high as 4.4% which is 2-times higher than that in general population. Most involve congenital
heart defects and central nervous system (Raymond and Mills. 1993, Konje and Taylor. 2001).
The cause for this is unclear.
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Premature separation of placenta deprives the fetus of oxygen and nourishment (Oyelese and
Ananth. 2006). In severe cases Apgar scores and cord blood pH values are often low due to
antenatal hypoxia and blood loss (Spinillo et al. 1993, Toivonen et al. 2002, Matsuda et al. 2003,
Allred and Batton. 2004). In one study the risk for intrapartum asphyxia with placental abruption
was 3.7-fold. Three percent of asphyctic newborns and 0.7% of controls had placental abruption
(Heinonen and Saarikoski. 2001). Intrapartum asphyxia may lead to long-term consequences
among survivors. Neonates born after placental abruption are more likely to develop cystic
periventricular leucomalasia or intraventricular hemorrhage (Spinillo et al. 1993, Gibbs and
Weindling. 1994). The risk increases with prematurity and low birth weight (Spinillo et al. 1993,
Gibbs and Weindling. 1994). Severe abruption increases the risk for cerebral palsy (Spinillo et
al. 1993, Thorngren-Jerneck and Herbst. 2006). Placental abruption is also associated with
sudden infant death syndrome (Klonoff-Cohen et al. 2002, Getahun et al. 2004).
Etiology
Placental abruption seems to be a multifactorial disease. Its etiology is not fully understood but
impaired placentation, placental insufficiency, intrauterine hypoxia, and uteroplacental
underperfusion are the key mechanisms causing abruption (Ananth et al. 1997, Kramer et al.
1997, Rasmussen et al. 1999, Ananth et al. 2006a). Abruption results from a rupture of maternal
decidual artery causing a dissection of blood at the decidual-placental interface, around placental
margin, or behind the membranes (Faye-Petersen et al. 2006). Acute vasospasm of small vessels
may be one event immediately preceding placental separation. Thrombosis of the decidual
vessels with associated decidual necrosis and venous hemorrhage also are often present (Oyelese
and Ananth. 2006). In some cases, blunt trauma or rapid decompression of the overdistended
uterus cause abruption but in most cases placental abruption seems to be a consequence of a
long-standing process perhaps dating back to the first trimester (Ananth et al. 2006b).
Immunological rejection
Immunological defects may play a role in the origin of placental abruption (Matthiesen et al.
1995, Steinborn et al. 2003b). These defects may lead to an excessive maternal inflammatory
response with increased release of cytokines and result in a chain of events including shallow
trophoblast invasion, defective spiral artery remodeling, placental infarctions and thrombosis
(Matthiesen et al. 2005). Excessive activation of the immune system may suggest past exposure
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to major antigens (Steinborn et al. 2004). Cell-mediated immunity is suppressed and humoral
immune response is upregulated in normal pregnancy but not in placental abruption (Matthiesen
et al. 1995, Steinborn et al. 2004). This can then lead to exaggerated maternal immune rejection
of the fetus, activation of fetal monocytes and release of inflammatory agents (Steinborn et al.
2004, Nielsen et al. 2007). Trophoblastic cells interact in the decidua with natural killer (NK)
cells which express receptors that recognize combinations of human leukocyte antigens (HLA).
HLA-G levels, decisive factors for the avoidance of rejection of the fetus, are strongly decreased
in women with placental abruption (Steinborn et al. 2003a). High level of soluble HLA-G is
needed to switch cytokine profile towards Th-2 response. If signaling between trophoblastic cells
and NK cells remains poor it causes insufficient trophoblast invasion and defective spiral artery
remodeling in early pregnancy. This may lead to hypoxic and dysfunctional placenta, placental
infarction and thrombosis, and finally, generalized inflammation, in which systemic endothelial
dysfunction is an essential component (Matthiesen et al. 2005, Redman and Sargent. 2005). This
suggests that placental abruption may result from placentation failure caused by flawed maternal
immune response to paternal antigens (Baumann et al. 2000). An excessive activation of the
immune system in placental abruption may suggest past exposure to strong superantigens
(Steinborn et al. 2004).
Inflammation
Placental abruption may be a manifestation of acute or chronic inflammatory process (Ananth et
al. 2006a). Infections and tissue injury cause a rapid release of various bioactive mediators at the
maternal-fetal interface (Nakatsuka et al. 1999, Ananth et al. 2006a). Neutrophils and
macrophages are increased in placentas of women with abruption compared to controls (Ananth
et al. 2006b). Oxidative stress and products of vascular activation and coagulation such as
thrombin may have similar effects (Ananth et al. 2006a). Abruption is associated with a
thrombin-enchanced expression of interleukin (IL)-8, a potent neutrophil chemoattractant, which
leads to a marked infiltration of decidual neutrophils (Rosen et al. 2002). Increased production of
proinflammatory cytokines such as tumor necrosis factor (TNF)-  and IL- 1 can stimulate the
production of matrix metalloproteinases (MMP) by trophoblasts and other cell types (Ananth et
al. 2006a). Increased premature production of MMP may result in the destruction of the
extracellular matrix and cell to cell interactions that lead to premature detachment (Ananth et al.
2006a). MMPs seem to play important roles in normal placental detachment (Ananth et al.
2006a). Reduced MMP activity is known to be associated with retained placentas in animals
(Maj and Kankofer. 1997). In a recent study 51% of women with preterm abruption (<37 weeks)
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and 44% of women with term abruption ( 37 weeks) had acute inflammation-associated
condition or chronic clinical process, compared to 37% of control women with preterm delivery
and 255 of control women with term delivery (Ananth et al. 2006a).
C-reactive protein (CRP) is an objective and sensitive marker of infection and inflammation
(Kluft and de Maat. 2002, Pitiphat et al. 2005). The levels and kinetics of CRP in cases of
placental abruption have not been studied, although CRP has been implicated in many other
pregnancy complications such as pre-eclampsia, gestational diabetes and preterm delivery with
or without chorioamnionitis (Loukovaara et al. 2003, Qiu et al. 2004a, Qiu et al. 2004b, Pitiphat
et al. 2005). Chlamydiae are common pathogens linked to chronic inflammatory disease
(Paavonen and Eggert-Kruse. 1999, Hammerschlag. 2007, Meyers et al. 2007). C. pneumonia
antibodies have been increased in women with preeclampsia in some (Heine et al. 2003, Goulis
et al. 2005) but not all studies (Teran et al. 2003, Raynor et al. 2004). C. trachomatis has been
linked to several adverse pregnancy outcomes (McGregor and French. 1991, Claman et al. 1995,
Gencay et al. 2000, Karinen et al. 2005). However, there is no data concerning placental
abruption and chlamydiae.
Vascular disease
Normal placentation requires trophoblast invasion of maternal spiral arteries, and development
of a high-flow, low-resistance uteroplacental circulation (Eskes. 1997). Vascular remodeling
occurs under the influence of several proangiogenic and antiangiogenic factors (Zygmunt et al.
2003, Lambert-Messerlian and Canick. 2004, Lam et al. 2005, Levine and Karumanchi. 2005,
Redman and Sargent. 2005). The former factors, i.e. placental growth factor (PlGF) and vascular
endothelial growth factor (VEGF), promote the formation of placental blood vessels and also the
invasion of trophoblasts in the spiral arteries (Zygmunt et al. 2003, Lam et al. 2005, Redman and
Sargent. 2005). Antiangiogenic factors include soluble fms-like tyrosine kinase 1 (sFlt-1) which
binds biologically active forms of PlGF and VEGF (Levine and Karumanchi. 2005), and soluble
endoglin (sEng) which blocks the binding of transforming growth factor isoforms to endothelial
receptors (Venkatesha et al. 2006). In placental abruption the trophoblast invasion in the spiral
arteries and consequent early vascularization is defective (Dommisse and Tiltman. 1992, Kraus
et al. 2004). It appears that PlGF deficiency and sFlt-1 excess may result from placental hypoxia
associated with incomplete remodeling of maternal spiral arteries. The incomplete remodeling of
arteries causes high resistance to uterine artery blood flow which may predispose to vascular
rupture in the placental bed leading to placental abruption (Dommisse and Tiltman. 1992, Eskes.
1997, Signore et al. 2006). This mechanism causes “a classic abruption” with arterial bleeding
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and usually with more severe symptoms (Elliott et al. 1998, Hladky et al. 2002). Placental
abruption can also be caused by a venous bleeding from marginal lakes around the edge of the
placenta leading often to preterm birth (Elliott et al. 1998, Hladky et al. 2002).
Risk factors
Although many risk factors for placental abruption are well known, the cause for this serious
complication often remains unexplained. Also, abruption often happens suddenly and is
unexpected. The pathogenesis of placental abruption may be multifactorial and may vary in
women with different risk factors. The known or suspected risk factors for placental abruption
are summarized in Tables 1, 2 and 3 (Kåregård and Gennser.1986, Saftlas et al. 1991, Miller et
al. 1995, Hemminki and Meriläinen. 1996, Ananth et al. 1997, Hulse et al. 1997, Kramer et al.
1997, Ananth et al. 1999b, Kupferminc et al. 1999, Ray and Laskin. 1999, Baumann et al. 2000,
Kyrklund-Blomberg et al. 2001, Lydon-Rochelle et al. 2001, Pandian Z et al. 2001, Campbell
and Templeton. 2004, Steegers-Theunissen et al. 2004, Ananth et al. 2005a, Casey et al. 2005,
Shevel et al. 2005, Lindqvist and Happach. 2006, Robertson et al. 2006, Ananth and Cnattingius.
2007, Ananth et al. 2007b, Burd et al. 2007).
Smoking
Approximately 10-20% of women in industrialized countries smoke during pregnancy (Ananth
and Cnattingius. 2007); in Finland the rate is approximately 15% (Stakes 2006). Smoking is a
well known risk factor for placental abruption and also for many other adverse pregnancy
outcomes, including infertility, spontaneous abortion, low birth weight, preterm delivery, and
long term physical and developmental disorders in infants (Ananth et al. 1999a). The association
with placental abruption and smoking was first reported in 1976 (Meyer et al. 1976).
Approximately 5% of all perinatal deaths are attributable to maternal smoking largely due to
placental abruption (Andres and Day. 2000). Smoking is also associated with a 2.5-fold increase
in severe abruption resulting in fetal death (Raymond and Mills. 1993). Studies have shown that
the relative risk for placental abruption associated with maternal smoking during pregnancy
varies from 1.5 to 2.5 (Voigt et al. 1990 Ananth et al. 1999a, Tuthill et al. 1999, Mortensen et al.
2001, Ananth and Cnattingius. 2007) with a strong dose dependency (Kyrklund-Blomberg et al.
2001, Ananth and Cnattingius. 2007). However, there seems to be a threshold effect at
approximately 10 cigarettes per day after which the risk remains relatively constant (Ananth et
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al. 1999a). Also, the duration of smoking is associated with an increasing incidence of placental
abruption (Naeye. 1980) although the risk is largely confined to the current pregnancy (Ananth
and Cnattingius. 2007). Quitting smoking before pregnancy or early in pregnancy reduces the
risk of abruption to the level of nonsmokers (Naeye. 1980, Andres and Day. 2000, Ananth and
Cnattingius. 2007). This suggests that the adverse effects of maternal smoking are largely due to
a direct toxic effect of smoking during pregnancy (Ananth and Cnattingius. 2007).
Although the mechanisms explaining the association between smoking and placental abruption
remain largely speculative, it is known that smoking increases homocysteine levels in the
plasma, and this may play a role (Ray and Laskin. 1999). Hyperhomocysteinemia can induce
endothelial cell injury and dysfunction leading to local thromboembolism and defects within the
placental vascular bed (de Vries et al. 1997). Also, the direct effect of smoking on placental
abruption may be mediated through vasoconstrictive effects of nicotine on uterine and umbilical
arteries as well as carboxyhemoglobin which interferes with oxygenation. Nicotine and carbon
monoxide (CO) cross the placenta. The levels of nicotine and CO in the fetal circulation are 15%
higher than those in blood (Luck et al. 1985, Andres and Day. 2000). The concentrations of
nicotine amniotic fluid can be 88% higher than in maternal plasma (Luck et al. 1985). Nicotine
decreases the flow in uterine and umbilical arteries causing changes in the fetal oxygenation and
acid-base balance. Fetal heart rate decreases and mean arterial pressure increases (Andres and
Day. 2000). CO binds to hemoglobin to form carboxyhemoglobin. Also this agent decreases fetal
oxygenation (Andres and Day. 2000). The hypoxic changes caused by nicotine and CO can lead
to placental infarcts, common among smokers, suggesting that increased capillary fragility might
result in arterial rupture leading to placental abruption (Naeye. 1980, Kaminsky et al. 2007). In
placentas of smoking women the perivillous knotting in syncytiotrophoblasts may be caused by
an attempt by the villi to increase surface area through angiogenesis and neovascularization
(Kaminsky et al. 2007). Placental function is impaired although placental weight is increased in
smoking women which may be due to adaptive angiogenesis in peripheral villous tree (Pfarrer et
al. 1999). This is reflected by increased levels of proangiogenic PlGF and reduced levels of
antiangiogenic sEng and sFlt-1 (Levine et al. 2006). Smokers also have lower concentrations of
cellular fibronectin (Lain et al. 2003), which connects trophoblast to the uterine decidua at the
site of implantation (Eskes. 1997).
According to a meta-analysis 15% to 25% of placental abruption episodes may be attributable to
cigarette smoking (Ananth et al. 1999a). Thus, a considerable proportion of placental abruption
episodes could be prevented if women quit smoking during pregnancy. No data exist of spouse
smoking and placental abruption.
22
Hypertensive complications
Hypertensive disorders in pregnancy, i.e. chronic hypertension, chronic hypertension with
superimposed preeclampsia, pregnancy induced hypertension (PIH), and preeclampsia have all
been found to be risk factors for placental abruption in many but not all studies (Ananth et al.
1996, Ananth et al. 1997, Kramer et al. 1997, Ananth et al. 1999a, Ananth et al. 2007b).
Comparison of these studies is problematic since definitions vary remarkably.
Chronic hypertension complicates 0.3-0.8% of pregnancies and increasing maternal age and
parity increase the risk (Ananth et al. 2007b). Smoking and the black race increase the risk
(Ananth et al. 2007b). In some (Ananth et al. 1996, Kramer et al. 1997, Ananth et al. 2007b) but
not all (Ananth et al. 1997) studies chronic hypertension has been a risk factor for placental
abruption. In one study the rate of abruption among women with or without chronic hypertension
was 1.56 % and 0.6 % in singleton pregnancies, respectively (Ananth et al. 2007b). After
adjustment for potential confounders women with chronic hypertension were at 2.4-fold
increased risk for abruption (Ananth et al. 2007b). In another study women with chronic
hypertension had no increased risk for abruption (RR 1.4; 95% CI 0.5-3.6) (Ananth et al. 1997).
Although chronic hypertension alone has not been a risk factor for placental abruption in all
studies, chronic hypertension with superimposed preeclampsia has increased the risk for
placental abruption 2.8- to 7.7-fold in several studies (Ananth et al. 1997, Ananth et al. 2007b).
Severe preeclampsia is a strong risk factor for placental abruption (Ananth et al. 1997, Ananth et
al. 1999a). However, PIH and mild preeclampsia are risk factors for placental abruption in some
(Kramer et al. 1997) but not all studies (Ananth et al. 1997, Ananth et al. 1999a). Comparison of
the studies is difficult due to different criteria used for preeclampsia (Ananth et al. 1996, Ananth
et al. 1997, Kramer et al. 1997, Ananth et al. 1999a). The risk for abruption is further increased
among women who have hypertensive disorder and who smoke (Ananth et al. 1999a). In two
previous Finnish studies chronic hypertension or PIH showed borderline association with
placental abruption (Ylä-Outinen et al. 1987, Toivonen et al. 2002). One of the two studies found
strong association between preeclampsia and placental abruption (Toivonen et al. 2002).
Hyperhomocysteinemia and thrombophilia
Homocysteine is an intermediate product in the metabolism of the essential amino acid
methionine (Steegers-Theunissen et al. 2004). Homocysteine is methylated to methionine and
this metabolism involves 5,10-methylenetetrahydrofolate reductase (MTHFR), folate, vitamins
B6 and B12 (Ray and Laskin. 1999, Eskes. 2001). Hyperhomocysteinemia induces endothelial
cell injury and dysfunction and leads to atherosclerosis and thromboembolism (de Vries et al.
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1997). There is an association between hyperhomocysteinemia and placental abruption
(Goddijn-Wessel et al. 1996, de Vries et al. 1997, Ray and Laskin. 1999, Vollset et al. 2000,
Steegers-Theunissen et al. 2004). The association is stronger with shorter interval between
sampling and delivery (Vollset et al. 2000) but the time of testing should be at least > 10 weeks
postpartum (de Vries et al. 1997). Hyperhomocysteinemia is a strong indicator of folate and B12
deficiency (Ray and Laskin. 1999). According to a meta-analysis folate deficiency may also be a
risk factor for placental abruption (OR 25.9, 95% CI 0.9-736.3) (Ray and Laskin. 1999). In
another study, high red cell folate decreased the risk for placental abruption (Steegers-
Theunissen et al. 2004). In some studies, but not all, vitamin B12 deficiency has been a risk
factor for placental abruption (Ray and Laskin. 1999, Steegers-Theunissen et al. 2004). Young
women with folate deficiency and hyperhomocysteinemia may be prone to endothelial
dysfunction including placental vasculature (Ray and Laskin. 1999). Although plasma
homocysteine levels can be lowered by administration of vitamin B6 and folate (Eskes. 2001),
older large prospective studies have failed to show any association between folate
supplementation and placental abruption (Konje and Taylor. 2001). However, a recent
Norwegian study showed that women who used folic acid or multivitamin supplements during
pregnancy had 26% lower risk of developing placental abruption than women who had not used
such supplements (Nilsen et al. 2008).
It is known that inherited and acquired thrombophilias increase the risk of venous
thromboembolism and adverse pregnancy outcome, i.e. early pregnancy loss, preeclampsia,
intrauterine growth restriction (IUGR), stillbirth, or placental abruption (Robertson et al. 2006,
Ulander et al. 2006). One of the early studies found that 65% of women with preeclampsia,
IUGR, unexplained stillbirth, or placental abruption had heritable or acquired thrombophilia
(Kupferminc et al. 1999). The risk found in individual studies has varied due to different study
designs (Robertson et al. 2006). Thrombophilias associated with abruption include MTHFR
deficiency, factor V Leiden mutation, prothrombin gene mutation, protein S and protein C
deficiency, antithrombin deficiency, lupus anticoagulant, and anticardiolipin antibodies (Oyelese
and Ananth. 2006). Homozygous MTHFR point mutation 677 C to T transition has been
associated with placental abruption in several (Ray and Laskin. 1999, Eskes. 2001, Nurk et al.
2004) but not all studies (Kupferminc et al. 1999, Jääskelainen et al. 2006). Some studies have
shown an association between placental abruption and heterozygous factor V Leiden mutation
(Kupferminc et al. 1999, Facchinetti et al. 2003, Robertson et al. 2004). However, in a Finnish
study M385T polymorphism in the factor V gene, but not Leiden mutation, was associated with
placental abruption (Jääskeläinen et al. 2004). A Swedish study of 102 women with abruption
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also failed to show any difference in factor V Leiden carrier rate between cases and controls
(Prochazka et al. 2003). The rate of heterozygous prothrombin gene mutation is increased 8- to
9-fold among women with placental abruption (Kupferminc et al. 1999, Kupferminc et al. 2000).
There is insufficient data of other thrombophilias and placental abruption (Robertson et al.
2006). The combination of hyperhomocysteinemia and thrombophilia increases the risk of
placental abruption 3- to 7-fold (Eskes. 2001).
Chorioamnionitis
Clinical diagnosis of chorioamnionitis may be difficult (Smulian et al. 1999) and can only be
confirmed histologically (Smulian et al. 1999). However, micro-organisms are isolated in only
70% of placentas with histologic chorioamnionitis (Smulian et al. 1999). In some cases
histologic inflammation may be due to a variety of noninfectious causes such as fetal hypoxia,
amniotic fluid pH changes, immunologic responses to fetal tissues, and meconium (Smulian et
al. 1999). Chorioamnionitis may precede abruption or abruption may precede chorioamnionitis,
or the two conditions may be unrelated and present simultaneously (Darby et al. 1989). Direct
bacterial colonization of the decidua with tissue inflammation may initiate a process that results
ultimately in placental abruption (Darby et al. 1989). Sometimes a subclinical decidual
thrombosis may initiate an inflammatory process (Darby et al. 1989). Nevertheless, infection
activates cytokines such as IL and TNF. These cytokines upregulate the production and activity
of MMPs in the trophoblast (Nath et al. 2007). This may result in destruction of the extracellular
matrix and cell to cell interactions which then may lead to disruption of the placental attachment
and finally to placental abruption (Nath et al. 2007).
Chorioamnionitis occurs three to seven times more likely in patients with abruption than in
controls (Darby et al. 1989, Saftlas et al. 1991). In a recent study the rate of histologically
confirmed chorioamnionitis among women with placental abruption was 30% (Nath et al. 2007).
Severe chorioamnionitis was strongly associated with placental abruption both in term and
preterm pregnancies (Nath et al. 2007). In another study, the rates of abruption among women
with or without intrauterine infection were 4.8% and 0.8% (Ananth et al. 2004). The attributable
proportion of intrauterine infections among all abruptions was 6.7% (Ananth et al. 2004).
Premature rupture of membranes
Preterm premature rupture of membranes (PROM) occurs in 3% of pregnancies and is
responsible for one third of all preterm births (Mercer. 2003). Approximately 4-12 % of patients
with preterm PROM develop placental abruption (Ananth et al. 1996, Mercer. 2003).  The risk of
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this complication increases with decreasing gestational age at membrane rupture (Mercer. 2003).
Women exposed to prolonged preterm PROM are at increased risk of developing abruption if the
latency between the time of membrane rupture and delivery exceeds 24 hours (Ananth et al.
2004).
Preterm PROM is often associated with ascending intrauterine infection. Recent evidence has
linked neutrophil infiltration in the decidua with preterm PROM and placental abruption. The
risk of abruption is 3.6-fold higher among women with preterm PROM, compared to women
with intact membranes (Ananth et al. 2004). When preterm PROM is accompanied with
intrauterine infection, the risk of abruption is 9-fold higher, compared to women with intact
membranes and no infection (Ananth et al. 2004). Although preterm PROM frequently precedes
abruption, sometimes placental abruption may lead to PROM (Rosen et al. 2002). Abruption
leads to marked infiltration of neutrophils in the decidua (Rosen et al. 2002). This influx of
neutrophils is a rich source of proteases that can degrade extracellular matrix, leading to preterm
PROM. Therefore, it is difficult to determine whether neutrophil infiltration into the decidua is
secondary to vascular disruption or whether it is the primary cause of abruption (Nath et al.
2007). In some women with preterm PROM reduction of uterine volume may lead to placental
abruption (Ananth et al. 1996).
Trauma
Physical trauma complicates 6-7 % of pregnancies (Pak et al. 1998, Schiff and Holt. 2002). Of
these, motor vehicle accidents account 66%, falls and assaults 33% (Pak et al. 1998). Domestic
violence is included in assaults and has been reported in 8-20 % of cases (Helton et al. 1987,
Parker et al. 1994, Rachana et al. 2002). Adverse pregnancy outcome after minor trauma occurs
in 1-5% of cases (Pak et al. 1998). Placental abruption is attributable to any trauma in
approximately 6% of all cases (Pearlman et al. 1990) and to major trauma in 20-25% of cases
(Vaizey et al. 1994), but is difficult to predict on the basis of the severity of the injury (Pearlman
et al. 1990). This makes placental abruption the second most common cause of fetal loss after
maternal death in pregnant trauma patients (Henderson and Mallon. 1998). The mechanism of
abruption in trauma cases is directly related to the injury. The relatively elastic uterus is able to
alter its shape in reaction to forces applied to the abdomen, whereas the less elastic placenta is
not. A shearing effect is therefore created, disrupting the attachment of placenta to the decidua
(Kingston et al. 2003). Placental abruption usually becomes manifest within 6 to 48 hours after
injury but can occur up to 5 days later (Higgins and Garite. 1984, Pearlman et al. 1990, Curet et
26
al. 2000). Placentas that are anteriorly placed are at increased risk for fetomaternal transfusion
(Pearlman et al. 1990).
External cephalic version is also associated with placental abruption although the risk is low. In a
recent review the incidence of placental abruption due to external cephalic version was only
0.12% (Collaris and Oei. 2004).
Others
Other prepregnancy risk factors for placental abruption include previous cesarean section (C/S)
and uterine anomaly (Green. 1989, Hemminki and Meriläinen. 1996). Also, the risk for placental
abruption is increased in the next pregnancy followed by birth of a small for gestational age
(SGA) newborn, premature birth, PIH, preeclampsia, or stillbirth (Rasmussen et al. 1999,
Lindqvist and Happach. 2006, Ananth et al. 2007a). This may indicate a common etiologic factor
for these conditions (Rasmussen et al. 1999). Both short and long interpregnancy intervals have
also been associated with increased risk of placental abruption (Rasmussen et al. 1999).
According to some studies cesarean first delivery increases the risk for placental abruption by
30-40% in the next pregnancy when compared to women with vaginal first delivery (Rasmussen
et al. 1999, Lydon-Rochelle et al. 2001, Getahun et al. 2006, Yang et al. 2007). According to a
Finnish study the risk is even higher, i.e. 2.4-fold among primiparous and 3.9-fold among
multiparous women (Hemminki and Meriläinen. 1996). If the interpregnancy interval is less than
one year the risk of abruption is increased by 52% in women with vaginal first delivery and by
111% in women with cesarean first delivery (Getahun et al. 2006). Uterine low segment scar
may impair placental attachment, and therefore increase the risk for abruption (Rasmussen et al.
1999, Lydon-Rochelle et al. 2001).
Although mentioned in some textbooks (Green. 1989), the most recent studies have not
demonstrated any association between placental abruption and congenital uterine malformation.
Abnormal fusion of the Müllerian ducts causes varying degrees of uterine anomalies (Heinonen
et al. 2000) present in 0.1-2% of all women (Acien. 1997). It may be that uterine malformation
leads to poor decidualization and placentation at the site of implantation. Also the contractibility
of malformed uterus may be disturbed or uncoordinated increasing the risk for placental
abruption (Dabirashrafi et al. 1995).
Other pregnancy related risk factors for placental abruption are placenta previa, bleeding during
pregnancy, multiple pregnancy, and alcohol and cocaine use (Kaminski et al. 1976, Sipilä et al.
1992, Miller et al. 1995, Baumann et al. 2000, Ananth et al. 2001, Salihu et al. 2005).
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Placenta previa is a notable risk factor for placental abruption (Konje and Taylor. 2001) although
not all studies confirm this (Oyelese and Ananth. 2006). Approximately 10% of women with
placenta previa have coexisting abruption (Konje and Taylor. 2001). In one study of the risk
factors for placental abruption, uterine bleeding > 28 gestational weeks and placenta previa were
the strongest predictors (Baumann et al. 2000). Among women with placenta previa the risk was
3- to 4-fold, and among women with uterine bleeding > 28 weeks the risk was 12- to 19-fold
(Baumann et al. 2000). If women had uterine bleeding at < 28 weeks the risk for placental
abruption was 2-fold (Baumann et al. 2000). Bleeding in early pregnancy carries an increased
risk for abruption in later pregnancy (Ananth et al. 2006b). The presence of a subchorionic or
retroplacental hematoma in the first trimester ultrasound examination increases the risk for
subsequent placental abruption 6- to 11-fold (Ball et al. 1996, Nagy et al. 2003). This may reflect
a hematoma impairing normal placentation. On the other hand, a hematoma can result from
impaired placentation (Nagy et al. 2003).
The risk of placental abruption is 2- to 3-fold in twin pregnancies compared to singleton
pregnancies (Baumann et al. 2000, Ananth et al. 2001, Campbell and Templeton. 2004, Salihu et
al. 2005) although not all studies have confirmed this (Kramer et al. 1997). With increasing
multiplicity the likelihood of placental abruption increases but associated perinatal mortality
decreases (Salihu et al. 2005). The risk of preterm birth or SGA in twin pregnancies with
placental abruption is higher than among twin pregnancies without placental abruption (Ananth
et al. 2005b). The discordant growth of twins is a risk factor for placental abruption (Ananth et
al. 2003). The risk factor profiles for placental abruption seem to be different among singleton
births and twin births (Ananth et al. 2001). The abruption in multifetal pregnancies may have a
different mechanism (Ananth et al. 2001, Salihu et al. 2005).
Alcohol use during pregnancy is a known risk factor for fetal neurodevelopmental abnormalities,
several fetal malformations, and SGA (Kaminski et al. 1976, Halmesmäki. 1988, Sokol et al.
2003). Alcohol easily crosses placenta and may disturb the hormonal balance in the mother and
fetus (Gabriel et al. 1998). No safe amount of alcohol consumption during pregnancy has been
determined. In one study, the risk of stillbirth was higher among alcohol users, particularly due
to placental abruption (Kaminski et al. 1976). In another study, the risk for placental abruption
did not vary according to alcohol consumption (Kramer et al. 1997).
In the United States, the incidence of cocaine ingestion during pregnancy has been reported as
high as 10% in selected populations (Miller et al. 1995, Baumann et al. 2000). The risk for
placental abruption among cocaine users is 3.9- to 8.6-fold (Miller et al. 1995, Hulse et al. 1997)
and may result from vasoconstrictive effects of cocaine (Hladky et al. 2002). Although the
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relationship between placental abruption and cocaine use is confounded by other risk factors,
including use of other drugs, tobacco, and lack of prenatal care, cocaine use remains as an
independent risk factor (Hladky et al. 2002). Amphetamine use is also associated with placental
abruption probably due to similar mechanisms as cocaine use (Kuczkowski. 2003).
Table 1. Sociodemographic and behavioural risk factors for placental abruption based on





 Maternal age  35 years 1.3-2.6
 Maternal age <20 years 0.8-1.5
 Parity  3 1.0-1.6
 Black race 1.9
 White race 1.2
 Lower socio-economic status
 Unmarried or single mother 1.5-6.8
Behavioral
Cigarette smoking 1.5-2.5
 Alcohol use 2.8-3.4
 Cocaine use 3.9-8.6
 Trauma 17.3
 Unexplained infertility or infertility treatments 1.3-2.4
____________________________________________________________________________________________
Table 2. Maternal and historical risk factors for placental abruption based on published data.








 Folate deficiencies 25.9










 Placental abruption 10.2-25.8
_____________________________________________________________________________________________
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Table 3. Pregnancy associated risk factors for placental abruption based on published data. Odds








 Premature rupture of membranes 0.9-5.9
 Oligohydramnion 1.0-2.8
 Polyhydramnion 3.0-3.2
 Placenta previa 3.2-4.3
 Vaginal bleeding  28 gestational weeks 2.0-2.2
 Vaginal bleeding  28 gestational weeks 12.3-18.7
 Multiple gestation 2.0-2.9
 External version
 Male fetal gender 1.3
 Small for gestational age fetus 1.3-4.1
 Short umbilical cord 1.3-2.0
 Velamentous umbilical cord insertion 1.8-3.7
 Vena cava syndrome
_____________________________________________________________________________________________
Clinical presentation and diagnosis
Although the symptoms of placental abruption are typical and have been well described, they
can vary considerably from one patient to another (Baron and Hill. 1998).
Symptoms
Classic symptoms of placental abruption are vaginal bleeding, abdominal pain, uterine
contractions and tenderness (Baron and Hill. 1998). All of these symptoms are not invariably
present, and asymptomatic presentation does not exclude placental abruption (Baron and Hill.
1998, Oyelese and Ananth. 2006). The symptoms and their severity depend on the location of
abruption, whether it is revealed or concealed, and the degree of abruption (Oyelese and Ananth.
2006). Vaginal bleeding is present in 70-80% of cases (Baron and Hill. 1998, Konje and Taylor.
2001) and its amount correlates poorly with the degree of abruption (Oyelese and Ananth. 2006).
If the membranes are ruptured, blood stained amniotic fluid leeks into vagina (Konje and Taylor.
2001). Uterine tenderness or pain is present in 66% and tonic uterine contractions in 34% (Baron
and Hill. 1998). The presence of pain probably indicates extravasation of blood into the
myometrium (Konje and Taylor. 2001). The contractions are unusually frequent with a rate of
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more than five in 10 minutes (Konje and Taylor. 2001, Oyelese and Ananth. 2006). The presence
of uterine contractions may, however, be difficult to distinguish from general abdominal pain
associated with abruption. Abdominal pain is less common in posterior placentas (Konje and
Taylor. 2001).
Clinical signs
Four grades (0-3) of placental abruption have been described (Table 4) (adapted from Konje and
Taylor. 2001), the most severe form occurring in about 0.2% of pregnancies (Konje and Taylor.
2001).
Table 4. Grading of placental abruption
_____________________________________________________________________________
Grade                        Description
_____________________________________________________________________________________________
0  Asymptomatic, a small retroplacental clot
1  Vaginal bleeding, uterine hypertonus and tenderness may be present; no signs of
  maternal or fetal distress
2  Vaginal bleeding possible, no signs of maternal shock; signs of fetal distress present
3  Vaginal bleeding possible, uterine hypertonus, “wooden-hard” uterus on palpation,
  persistent abdominal pain, maternal shock and fetal death, coagulopathy in 30% of cases
_____________________________________________________________________________
Placental abruption is often confirmed by gross examination of delivered placenta. In recent
abruption the inspection of placenta demonstrates a crater-like depression on the maternal
surface of the placenta covered by dark clotted blood, so called “delle” (Eskes. 1997). In older
abruptions fibrin deposits appear on the site of abruption (Oyelese and Ananth. 2006). A totally
abrupted placenta may not differ on the maternal surface from a normal placenta at delivery
(Eskes. 1997).
Bleeding may occur into the uterine myometrium, leading to a purple colored uterus, so called
Couvelaire uterus (Oyelese and Ananth. 2006) Such an uterus contracts poorly which can result
in postpartum hemorrhage (Konje and Taylor. 2001).
Ultrasound
If placental abruption is suspected based on clinical symptoms, ultrasound examination is often
performed in an attempt to visualize the extent of subchorionic or retroplacental hematoma. In
some cases, placental abruption may be detected based on ultrasonographic findings even in
31
asymptomatic patients (Oyelese and Ananth. 2006). The ultrasonographic appearance of
abruption depends on the size and location as well as the age of the hematoma (Nyberg et al.
1987). The appearance of hematoma in the acute phase of abruption is from hyperechoic to
isoechoic when compared with the placenta. When the hematoma resolves it becomes more
hypoechoid within 1 week and sonolucent within 2 weeks (Nyberg et al. 1987). Small abruptions
or acute revealed abruptions are often not detectable by ultrasound (Oyelese and Ananth. 2006).
Concealed hemorrhage may be more easily seen by ultrasound (Glantz and Purnell. 2002).
Despite improvement in sonographic equipments the sensitivity of the diagnosis of abruption has
not improved (Glantz and Purnell. 2002). In one study ultrasound correctly diagnosed abruption
only in 25% of cases (Glantz and Purnell. 2002). When a clot was visualized by ultrasound, the
positive predictive value for abruption was 88% (Glantz and Purnell. 2002). Also, when a
subchorionic or retroplacental hematoma was identified by ultrasound the management was
more aggressive and perinatal outcome was worse (Glantz and Purnell. 2002). It may be that
positive sonographic findings with more severe abruption lead to unnecessary intervention which
impairs neonatal outcome mainly due to prematurity (Glantz and Purnell. 2002). Although
ultrasound is not accurate in the diagnosis of abruption it is useful in monitoring cases managed
expectantly and in excluding coincident placenta previa (Konje and Taylor. 2001).
Cardiotocographic changes
In severe cases of placental abruption the fetus presents with heart rate abnormalities. A variety
of fetal cardiotocographic (CTG) patterns have been described in association with placental
abruption and fetal distress, and may include repetitive late or variable decelerations, decreased
beat-to-beat variability, bradycardia, or sinusoidal fetal heart rate pattern (Oyelese and Ananth.
2006). Abnormal CTG in association with placental abruption predicts poor fetal outcome, even
death (Manolitsas et al. 1994). On the other hand, conservative expectant management seems to
be safe in preterm pregnancies with placental abruption and normal CTG (Manolitsas et al.
1994).
Placental histopathology
Histopathology of abrupted placentas often shows evidence of acute and chronic lesions (Ananth
et al. 2006b). Acute lesions include neutrophil infiltration of the chorionic plate and chronic
lesions include placental infarcts in the decidua (Ananth et al. 2006b). Chronic lesions develop
due to a lack of adequate trophoblastic invasion (Dommisse and Tiltman. 1992). Histological
signs of chorioamnionitis and deciduitis with neutrophil infiltration are associated with placental
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abruption in one third of the cases (Kaminsky et al. 2007, Nath et al. 2007). Acute atherosis in
spiral arteries leads to distinctive necrotizing decidual lesions (Eskes. 1997, Ananth et al. 2006b)
ultimately leading to vascular thrombosis, placental infarcts and fibrin deposits (Darby et al.
1989, Eskes. 1997, Kaminsky et al. 2007).
Intervillous thrombosis results from intraplacental hemorrhage from villous capillaries and is
associated with chorionic villous hemorrhage. Intervillous thrombosis is more common in
smoking women with placental abruption (Kaminsky et al. 2007). This may further reduce
uteroplacental and fetal blood flow leading to chronic underperfusion. Chronic hypoxia is
manifested by increased villous fibrosis and trophoblast knotting (Kaminsky et al. 2007). One
study found that necrosis in the decidua basalis at the margin of the placenta was most frequent
in smoking women suggesting that such necrosis could initiate placental abruption (Naeye.
1980).
Management
The management of placental abruption depends on the extent of abruption, gestational age, and
maternal and fetal condition. The management should be individualized (Oyelese and Ananth.
2006). Severe abruption with intrauterine fetal death, regardless of gestational age, should be
managed by vaginal delivery if there are no contraindications, (Konje and Taylor. 2001, Oyelese
and Ananth. 2006). Labor usually progresses rapidly due to continuous contractions (Hladky et
al. 2002) and if not, amniotomy can be performed. Augmentation of uterine contractions by
oxitocin infusion or ripening of cervix by prostaglandins must be done cautiously as the risk of
uterine rupture may exist in placental abruption (Konje and Taylor. 2001). Concealed bleeding
into the myometrium, maternal tachycardia, or hypertension may lead to underestimation of the
blood loss (Konje and Taylor. 2001). Intravenous cannule should be inserted and blood products
and coagulation factors given if necessary (Hladky et al. 2002, Oyelese and Ananth. 2006).
When labor does not progress rapidly or mother is unstable C/S may be necessary to avoid
worsening of the coagulopathy (Hladky et al. 2002, Oyelese and Ananth. 2006). DIC is present
in approximately 35% of cases of severe placental abruption (Konje and Taylor. 2001). The
patient should be monitored closely after vaginal or operative delivery since severe hemorrhage
occurs in 25% of the cases (Konje and Taylor. 2001). Hysterectomy may occasionally be
necessary (Konje and Taylor. 2001, Oyelese and Ananth. 2006).
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If the fetus is alive and pregnancy near term, prompt delivery is indicated. In cases of fetal or
maternal compromise, cesarean delivery should be performed. If both fetal and maternal
conditions are reassuring, vaginal delivery is reasonable. Established labor should be allowed to
progress, otherwise induction of labor should be considered (Oyelese and Ananth. 2006). If
abruption is suspected on the basis of an incidental finding on ultrasound in a term pregnancy,
vaginal delivery is indicated (Hladky et al. 2002, Oyelese and Ananth. 2006).
Partial placental abruption at 20-34 weeks of gestation may be managed conservatively if
maternal and fetal conditions are reassuring. Patient must be closely monitored and fetal growth
followed (Konje and Taylor. 2001, Hladky et al. 2002, Oyelese and Ananth. 2006). At 24 to 34
weeks, steroids to promote fetal lung maturation should be given. It may be possible to discharge
these patients if fetal condition is reassuring after patients have remained stable for several days
(Hladky et al. 2002, Oyelese and Ananth. 2006). If the bleeding episodes are recurrent but fetal
condition is satisfactory, induction is recommend at 37-38 gestational weeks (Konje and Taylor.
2001). Tocolytics such as -sympathomimetics, atosiban, or magnesium sulfate can be used in
selected cases of preterm placental abruption (Hladky et al. 2002).
Pregnant women should be followed for a minimum of 4 hours after abdominal or other trauma.
If uterine contractions, vaginal bleeding, or fetal heart rate changes occur the follow-up should
be extended (Oyelese and Ananth. 2006). All rhesus negative patients with placental abruption
should receive anti-D immunoglobulin within 72 hours (Konje and Taylor. 2001).
Prediction
It is likely that in the majority of cases placental abruption is a long-standing process dating back
to the first trimester (Oyelese and Ananth. 2006). Therefore, it would be of clinical importance if
this condition could be predicted before it manifests clinically. Many clinical variabes and
findings have been studied to predict the risk of placental abruption.
Family history
There is some evidence that placental abruption could occur in families (Toivonen et al. 2004a,
Lindqvist and Happach. 2006). According to one study placental abruption appears to cluster in
families with an index patient with recurrent placental abruption (Toivonen et al. 2004a).
According to another study 5% of women with abruption report first degree relatives with this
complication (Lindqvist and Happach. 2006).
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The high prevalence of thrombophilia among women with placental abruption supports the idea
of genetic background (Robertson et al. 2006). In one study 20% of women with placental
abruption reported first degree relatives with venous thrombosis compared to only 6.7% of the
controls (Prochazka et al. 2003). Genetic studies involving the use of candidate gene approach
have shown a positive association between placental abruption and polymorphisms of the nitric
oxide synthase gene (Yoshimura et al. 2001, Hillermann et al. 2005) although this was not
confirmed in the Finnish study (Toivonen et al. 2005). Also, it has been shown that low-activity
haplotype of the microsomal epoxide hydrolase gene is protective against placental abruption
(Toivonen et al. 2004b).
History of placental abruption
Perhaps the most accurate predictor of abruption is a placental abruption in prior pregnancy
(Oyelese and Ananth. 2006). Women with a history of abruption have 7- to 20-fold risk of
abruption in a subsequent pregnancy (Kåregård and Gennser. 1986, Ananth et al. 1996,
Rasmussen et al. 1997) and this risk elevation is not related to smoking habits (Ananth and
Cnattingius. 2007). Placental abruption recurs in 3-17% after one episode and in 19-25% after
two episodes (Kåregård and Gennser. 1986, Ananth et al. 1996, Rasmussen et al. 1997,
Rasmussen et al. 2000, Konje and Taylor. 2001, Toivonen et al. 2004).
Women with unexplained abruption may benefit from screening for thrombophilias and
hyperhomocysteinemia (de Vries et al. 1997, Eskes. 2001, Oyelese and Ananth. 2006). Women
who screen positive for thrombophilia can be treated with heparin and aspirin in subsequent
pregnancies or with folate, vitamin B6, and B12 in the case of MTHFR deficiency or
hyperhomocysteinemia, although no clear benefit has been demonstrated (Eskes. 2001, Oyelese
and Ananth. 2006). Smoking should be stopped (Oyelese and Ananth. 2006). Because patients
with abruption have an increased risk of impaired uteroplacental perfusion in subsequent
pregnancies, serial growth scans every 4 weeks should be considered during the second half of
the pregnancy (Rasmussen et al. 2000, Rasmussen et al. 2001, Oyelese and Ananth. 2006). In
women with two or more prior abruptions, amniocentesis for lung maturity and delivery at about
37 weeks of gestation is recommended (Oyelese and Ananth. 2006).
Uterine artery flow measurement
Doppler evaluation of uterine arteries in the first and second trimester might be a useful
screening tool in the prediction of preeclampsia and SGA (Harrington et al. 1996, Martin et al.
2001, Papageorghiou et al. 2001, Madazli et al. 2005, Pilalis et al. 2007). There are also data to
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suggest that high uterine artery pulsatility index at 11-14 weeks or notching of the uterine artery
waveform at 20-24 gestational weeks could predict subsequent abruption (Harrington et al. 1996,
Pilalis et al. 2007) but these methods have not been universally accepted in the prediction of
placental abruption.
Biochemical markers
Elevated maternal serum alpha-fetoprotein (AFP) is associated with structural fetal anomalies,
including open neural tube defects, abdominal wall defects and congenital nefrosis (Chandra et
al. 2003). Yet, approximately 1% of patients have an elevated AFP level that cannot be
accounted for incorrect dates, structural or chromosomal abnormalities, or multiple gestation
(Chandra et al. 2003). This unexplained second-trimester elevation in maternal serum AFP may
be associated with subsequent adverse obstetric outcome including placental abruption (Katz et
al. 1990, van Rijn et al. 1999, Chandra et al. 2003, Dugoff et al. 2005, Smith et al. 2006).
Disruption at the fetal maternal interface permits transfer of AFP into the maternal circulation
(Chandra et al. 2003). Chronic villitis and vascular lesions of thrombosis or infarction have been
associated with elevated maternal serum AFP levels (Salafia et al. 1988). In a Finnish study,
elevated AFP levels (> 2.0 MoM) were detected in 17% of pregnancies with subsequent
placental abruption (Toivonen et al. 2002). In another study of women with preterm labor and
placental abruption AFP levels were higher than in other groups with preterm labor (Bartha et al.
1997). Authors suggested that AFP could be used as a marker for placental abruption (Bartha et
al. 1997), but so far this test has not been used for this purpose in clinical practise.
Maternal serum free beta human chorionic gonadotrophin ( -hCG) is commonly measured in
the second trimester to screen for chromosomal abnormalities (van Rijn et al. 1999, Dugoff et al.
2005). In case of normal chromosomes this test may be elevated in pregnancy complications,
such as in early fetal loss, preterm birth, PIH, preeclampsia, and SGA (Liu et al. 1999, van Rijn
et al. 1999, Chandra et al. 2003, Dugoff et al. 2004, Dugoff et al. 2005). There are also some
data linking high -hCG levels to placental abruption (Liu et al. 1999). Abnormal increased
levels of -hCG may be due to decreased placental perfusion (Chandra et al. 2003).
Theoretically, being purely a placental product (Liu et al. 1999, Chandra et al. 2003), -hCG
may hold promise for prediction of placental abruption.
Pregnancy-associated plasma protein A (PAPP-A), widely used in screening for chromosomal
abnormalities at 10-14 weeks of gestation (Dugoff et al. 2004, Pilalis et al. 2007), is a protease
for insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) (Dugoff et al. 2004). A recent
cohort study of 34,271 women indicated that women with first-trimester PAPP-A levels at the
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lowest fifth centile had an increased risk of placental abruption (Dugoff et al. 2004). In another
study low PAPP-A was detected in 29% at the lowest fifth centile and 43% at the lowest tenth
centile of women with placental abruption (Pilalis et al. 2007).
Proangiogenic placental growth factor (PlGF) and antiangiogenic soluble fms-like tyrosine
kinase-1 (sFlt-1) are the factors regulating placental angiogenesis throughout pregnancy.
Presence and function of PlGF is critical during cytotrophoblastic invasion (Madazli et al. 2005).
Soluble Flt-1 inhibits both PlGF and VEGF (Lam et al. 2005). Many studies have shown that the
circulating levels of sFlt-1 are increased and those of PlGF and VEGF are decreased often weeks
before onset of clinical preeclampsia (Levine et al. 2004, Thadhani et al. 2004, Signore et al.
2006, Wathen et al. 2006).  It is also possible that smoking may affect these vasoregulators
(Levine et al. 2006). In a recent study, decreased levels of PlGF and increased levels of sFlt-
1/PlGF ratios at 21st to 32nd weeks of gestation preceded subsequent placental abruption but only
in the women who also developed preeclampsia or PIH (Signore et al. 2006). Thus, it is not
known whether placental abruption itself is associated with changes in these markers.
Maternal serum activin A is a glycoprotein (Keelan et al. 2002) which has many biological
effects including tissue remodeling and regulation of trophoblast differentiation and invasion
(Keelan et al. 2002, Madazli et al. 2005). Activin A is produced primarily by the placental
trophoblast and its levels in maternal blood are elevated in preeclamptic patients (Madazli et al.
2005). One study reported two cases with placental abruption (without preeclampsia) who had
high activin A levels weeks before placental abruption (Florio et al. 2003). This calls further
studies on the value of this test in prediction of placental abruption.
Fibronectin is a glycoprotein synthesized in the endothelial cell (Madazli et al. 2005). With a
glycopeptide domain it connects trophoblast to the uterine decidua at implantation site (Eskes.
1997). The levels of fibronectin are high in women with preeclampsia, perhaps as a result of
endothelial damage (Madazli et al. 2005). The levels of fibronectin are also higher in women
with placental abruption (Kanayama and Terao. 1992) but clearly more research is needed.
Thrombomodulin is a vascular endothelial cell receptor for thrombin which neutralizes thrombin
clotting activity (Magriples et al. 1999). Thrombomodulin is a marker of endothelial cell damage
and has been localized to the placental syncytiotrophoblast (Magriples et al. 1999). The levels of
trombomodulin may be elevated in women with placental abruption (Magriples et al. 1999).
Kleihauer-Betke test is not sensitive enough and should not be used to diagnose placental
abruption (Emery et al. 1995, Magriples et al. 1999). D-dimer, a byproduct of clot lysis, has a
high negative predictive value for thromboembolic events (Nolan et al. 1993, Adema and Gebert.
1995) and may also be used in early diagnosis of placental abruption (Nolan et al. 1993). Also
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coagulation profile, i.e. platelet count, prothrombin time, partial thromboplastin time, and
fibrinogen level have been used in the prediction of placental abruption (Nolan et al. 1993,
Magriples et al. 1999) but their efficacy is not good enough for clinical purpose.
Risk factor analysis
Risk score analyses and mathematical modelling have been developed in order to predict
placental abruption (Baumann et al. 2000, Lindqvist and Happach. 2006). An analysis of 52
obstetric risk factors related to placental abruption was used to create a mathematical model
(Baumann et al. 2000). After multivariate analysis seven correlates overlapping between
primiparous and multiparous women remained in the model. These were uterine bleeding at <28
and >28 gestational weeks, placenta previa, male fetal gender, preterm labor, breech position,
and cigarette smoking. The strongest predictors of placental abruption were concomitant uterine
bleeding at > 28 gestational weeks and placenta previa (Baumann et al. 2000). The cumulative
risk could be calculated mathematically. In another study, each risk factor was given a score
from 1 to 3 depending of the odds ratio and a total score was calculated (Lindqvist and Happach.
2006). The potential limitation of these analyses is that both studies are retrospective. These
models may be useful in future management of high risk pregnancies if validated in prospective
studies (Baumann et al. 2000, Lindqvist and Happach. 2006).
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AIMS OF THE STUDY
The aims of this thesis were to determine
1. the incidence of placental abruption in a tertiary university hospital
2. the risk factors occurring before and during pregnancy ending in placental
 abruption
3. the clinical presentation of placental abruption
4. if placental abruption could be predicted by second-trimester maternal serum
 alphafetoprotein, free beta human chorionic gonadotrophin, soluble endoglin,
    soluble fms-like tyrosine kinase 1 and placental growth factor levels
5. if placental abruption could be predicted by first trimester maternal serum
                      C-reactive protein and chlamydial antibody levels
39
SUBJECTS AND METHODS
The studies were conducted with the approval of the Ethics Committee of the Department of
Obstetrics and Gynecology, Helsinki University Central Hospital. Study V was conducted in
collaboration with the National Public Health Institute, Oulu.
Subjects
Study I and Study II
All patients with a diagnosis of placental abruption (ICD-10 O45.0, O45.8, O45.9) were sought
among a total of 46,742 deliveries during 1997-2001 in Helsinki University Central Hospital
(Women’s Clinic and Maternity Hospital). The diagnosis was based on clinical symptoms and
signs and ultrasound examination, and was confirmed by the presence on one or more of the
following signs: postpartal retroplacental hematoma, Couvelaire uterus, or intrauterine
hematoma detected at cesarean section. Women delivering after 22 weeks of gestation or having
a newborn weighing more than 500g were included in the analysis. The duration of the gestation
calculated from the last menstrual period was confirmed based on ultrasound screening
examination performed at 11-13 weeks. The control group consisted of the next women who
gave birth before and after each index case, and who had no evidence of placental abruption.
Both groups included twin pregnancies. A total of 198 women with placental abruption and 396
control women were identified and included in the study (Table 5).
Study III and Study IV
All patients with a diagnosis of placental abruption were sought in Helsinki University Central
Hospital (Women’s Clinic and Maternity Hospital) database of 27,569 deliveries during 1997-
1999. Until 1999 maternal serum screening at 15-16 gestational weeks was offered to the whole
population to detect trisomy 21 and AFP-associated fetal malformations using AFP and free -
hCG as markers. Placental abruption was diagnosed and duration of the gestation was calculated
as described above. Women delivering after 22 weeks of gestation or having a newborn
weighing more than 500g were included. The control group consisted of the two women who
gave birth before and after each index case, and who had no evidence of placental abruption.
Women with multiple gestation were excluded. Among the study population none of the
newborns showed evidence of chromosomal abnormalities, neural tube defects, ventral wall
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defects, or congenital nephrosis. A total of 118 women with placental abruption and 236 control
women were identified. Of these, 57 case women and 108 control women were from Helsinki
city area and had MSAFP and MS -hCG measured and results available (Study III) and 42 cases
with subsequent placental abruption and 50 controls had serum samples collected for 21 trisomy
screening and had sera available for analyses of sEng, sFlt-1 and PlGF (Study IV) (Table 5).
Study V
Cases and controls were selected as described in Studies I and II. Twin pregnancies were
excluded from the both groups, and only women with normal pregnancies (i.e. deliveries  37
gestational weeks without signs of PIH, preeclampsia, chronic hypertension, IUGR, bleeding in
II/III trimester, chorioamnionitis or stillbirth) were included as controls. Thus, the final study
population consisted of 181 women with subsequent placental abruption and 261 control women
(Table 5). Serum samples were collected at 10-11 gestational weeks.
Table 5. Number of cases and controls in each study
___________________________________________________________________________
Study Time period Cases      Controls
___________________________________________________________________________
I & II 1997-2001 198 396
III 1997-1999 57 108
IV 1997-1999 42 50




Handling of clinical data
Relevant clinical data were recorded from the hospital charts. Chronic hypertension was defined
as blood pressure  140/90 mmHg before pregnancy or before the 20th week of gestation. PIH
was diagnosed if systolic blood pressure had increased by more than 30 mmHg or diastolic blood
pressure by more than 15 mmHg after 20th gestational week exceeding 140/90 mmHg, in the
absence of proteinuria (<0.3 g/L). Pre-eclampsia was defined as PIH with proteinuria ( 0.3g/L).
SGA or IUGR was defined as birth weight under the 10th percentile of the national standard
(Pihkala et al. 1989). Birth before 37 completed gestational weeks was defined as preterm. First
trimester bleeding was defined as bleeding before the 12th completed gestational week. Second
trimester bleeding was defined as bleeding between the 12th and 28th gestational weeks, and third
trimester bleeding as bleeding after the 28th week not immediately associated with placental
abruption. Placental localization was recorded during the screening ultrasound examination at
18-20 weeks of gestation and those with suspicion of placenta previa were re-examined during
the third trimester. Acute chorioamnionitis was defined on the basis of symptoms including
maternal fever of 38°C, increased heart rate of the mother and the fetus, uterine tenderness, foul
odor of the amniotic fluid, increased blood white cell count, and increased CRP concentration.
Preterm PROM was defined as a spontaneous rupture of the membranes before 37 completed
gestational weeks. Preterm PROM lasting more than 24 hours before delivery was considered
prolonged. PMR referred to intrauterine fetal death or newborns surviving < 7 days. Smoking
habits of the women and their partners and alcohol consumption of the women were
systematically recorded at the first antenatal clinic visit. All women and their partners who
smoked at least one cigarette per day were defined as smokers. Women who used more than two
doses of alcohol per week were defined as alcohol users.
Occupational level or socio-economic position was defined as higher (upper level administrative,
managerial or professional employees) or lower (lower level administrative or clerical
employees, skilled and unskilled manual workers and unclassified workers such as unemployed,
students, unknown occupation). Uterine malformations included uterine septum (partial or
complete), arcuate uterus, bicornuate uterus, didelphic uterus and unicornuate uterus. Uterine
malformations were diagnosed on the bases of pelvic examination, transvaginal ultrasound and
operative interventions. Subfertility referred to patients who had been examined for infertility or
who had used assisted reproductive technology. Assisted conception referred to patients who had
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undergone ovulation induction, intrauterine insemination, standard in-vitro fertilization or
intracytoplasmic sperm injection.
 Assays
Established assays were employed for the determination of a given marker, and the main
principles of the assays are shown in Table 6.
Alpha-fetoprotein and free beta-human chorionic gonadotrophin
Blood samples were collected from the antecubital vein. Sera were separated by centrifugation
and stored at +5 °C and analyzed within 24 h. MSAFP and MS -hCG were measured by
AutoDelfia automatic immunoassay system and fluoroimmunometric hAFP/free hCGbeta Dual
Kit (Perkin Elmer/Wallac, Turku). According to information from the manufacturer, the minimal
detectable dose for AFP was 0.1 mU/L and for -hCG 0.2 ng/ml. The intra- and interassay
coefficients of variation at the concentrations measured were below 4.4%. All serum samples
were analyzed in a single central laboratory. The patients with a risk of 1:350 or higher for
Down’s syndrome or an MSAFP-level > 2.5 multiples of median (MoM) were offered
counseling and amniocentesis.
Soluble endoglin, soluble fms-like tyrosine kinase 1 and placental growth factor
Sera were separated by centrifugation and stored at -20 °C. Serum specimens were randomly
allocated to batches and analyzed by enzyme-linked immunosorbent assays (ELISAs) for human
sEng, human sFlt-1 (sVEGF R1) and human PlGF, according to the manufacturer’s instructions
(R&D Systems, Inc., Minneapolis, USA). All samples were run in duplicates by a technician
blinded to pregnancy outcome, and the mean values of the duplicate samples were reported.
According to information from the manufacturer, the minimal detectable dose for sEng was
0.007 ng/ml and for PlGF 7 pg/ml while that for sFlt-1 was 5 pg/ml. The intra- and interassay
coefficients of variation at the concentrations measured were below 10%.
C-reactive protein and chlamydial antibodies
Serum samples of all pregnant women are collected during the first antenatal clinic visit (mean
10.4 gestational weeks) for routine screening, and stored at -25 ºC at the National Public Health
Institute serum bank. This serum bank covers over 98% of all pregnant women in Finland since
1983. Serum CRP levels were quantified using an immunofluorometric CRP kit (Innotrac Diag,
Turku, Finland). The sensitivity of the assay is 0.05 mg/L and its assay range is 0.05-50 mg/L.
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The intra- and interassay coefficients of variation at the concentrations measured were below
18%. Antibody analysis was done by randomly allocating the serum specimens to batches and
running in duplicates blinded to pregnancy outcome. Microimmunofluorescence test
(AniLabsystems, Helsinki) was used to analyze C. pneumoniae specific immunoglobulin G
(IgG) and immunoglobulin A (IgA) antibodies. A cut-off titer >16 was defined as a positive
result. C. trachomatis specific IgG and IgA and chlamydial heat shock protein 60 (CHSP60)
specific IgG serum antibodies were analyzed by enzyme linked immunosorbent assays (Elisa)
kits (Medac Diagnostika, Hamburg, Germany). Results were obtained as a mean absorbance of
duplicated samples at 450 nm. Less than 10% variation was seen in doublets (optical density
[OD] >0.2). Cut-off for a positive antibody level (=mean OD value of the negative control
+0.350) was defined as OD>0.4. The intra- and interassay coefficients of variation at the
concentrations measured were below 22% for C. trachomatis and CHSP60 IgG antibodies, and
below 18% for IgA antibodies.
Table 6. Assay characteristics
_____________________________________________________________________________
Marker  Assay principle Source of reagent
_____________________________________________________________________________________________
Alphafetoprotein  Fluoroimmunometric assay Perkin Elmer/Wallac, Turku
-human chorionic  Fluoroimmunometric assay Perkin Elmer/Wallac, Turku
    gonadotrophin
Soluble endoglin  Enzyme-linked immunosorbent assay  R&D Systems, Inc., Minneapolis
Soluble fms-like tyrosine  Enzyme-linked immunosorbent assay R&D Systems, Inc., Minneapolis
    kinase 1
Placental growth factor  Enzyme-linked immunosorbent assay R&D Systems, Inc., Minneapolis
C-reactive protein  Fluoroimmunometric assay Innotrac Diag, Turku
Chlamydia  trachomatis IgG  Enzyme-linked immunosorbent assay Medac Diagnostika, Hamburg
C. trachomatis IgA  Enzyme-linked immunosorbent assay Medac Diagnostika, Hamburg
C. trachomatis heat-shock  Enzyme-linked immunosorbent assay Medac Diagnostika, Hamburg
    protein 60
C. pneumoniae IgG  Microimmunofluorescence assay AniLabsystems, Helsinki




Categorical data were analysed by ²-test, Chi-square test, or Fisher’s exact probability test
(Studies I-II). To compare continuous variables, Student’s t-test was applied for normal
distributions and Mann-Whitney U-test for other types of distributions (Studies I-II). In Study I,
a multivariate logistic regression analysis was performed with placental abruption of the index
pregnancy as dependent variable and demographic and historic variables as independent
variables (Study I). All variables significant (p <0.05) by univariate analysis were entered into
the multivariate analysis. In Study II, a multivariate logistic regression analysis was performed
with placental abruption as the dependent variable and selected features of the index pregnancy
as independent variables. The calculations were performed with NCSS 2001 (NCSS Inc.,
Kaysville UT, USA).
In Study III, categorical data were analyzed by Chi-square test or Fisher’s exact probability test.
Continuous variables (e.g. MSAFP and MS -hCG) with skewed distribution were analyzed
either with non-parametric tests or with parametric tests after logarithmic transformation. P-
values of <0.05 were considered statistically significant. A logistic regression analysis was
performed with placental abruption as the dependent variable. Variables with a p-value  0.2 in
univariate analysis were used as independent variables. Binormal receiver operating
characteristic (ROC) curve was constructed to assess usefulness of various cutoffs of MSAFP.
The calculations were performed with NCSS 2004 (NCSS Inc., Kaysville, UT, USA).
In Study IV, categorical data were analyzed by the Chi-square test. Continuous variables with
normal distribution (age, body mass index and gestational age at screening) were analyzed by the
Student’s t-test. The angiogenic factors were analyzed with the Mann-Whitney U-test. P-values
of <0.05 were considered statistically significant. The calculations were performed with NCSS
2004 (NCSS Inc., Kaysville, UT, USA).
In Study V, Chi-square test was used to compare categorical variables between the study groups.
Continuous variables were compared by Student’s t-test. Distribution of CRP levels was skewed
and the comparisons were therefore done by non-parametric Mann-Whitney U-test. P-values of
<0.05 were considered statistically significant. Logistic regression analysis was used to estimate
the risk of placental abruption in relation to elevated CRP levels (upper quartile) and potential
confounding factors. The calculations were performed with SPSS for Windows 14.0.1 software
2006 (SPSS Inc., Chicago, Illinois, USA).
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RESULTS
Detailed results are given in the original publications and only the main results are summarized
here.
Prepregnancy risk factors for placental abruption (I)
The overall incidence of placental abruption was 0.42%. Placental abruption recurred in 8.8% of
the cases. Univariate analysis showed that compared to controls, women with placental abruption
were significantly more often older than 35 years (OR 1.7; 95% CI 1.1, 2.6), had lower
occupational level (OR 1.5; 95% CI 1.0, 2.1), were more often unmarried (OR 1.4; 95% CI 1.0,
2.0), and had more often had three or more deliveries (OR 2.6; 95% CI 1.4, 4.7). Smoking before
pregnancy was strongly associated (OR 2.0; 95% CI 1.3, 3.0) with placental abruption (Tables
7). Of selected gynecologic history variables uterine malformation (OR 9.4; 95% CI 2.0, 44) and
history of spontaneous abortion (OR 1.6; 95% CI 1.1, 2.4) were more common among cases by
univariate analysis (Table 7).
Chronic hypertension, coagulopathies, diabetes (types 1 or 2 or gestational) and subfertility
occurred equally commonly in both groups. Similarly, family history of hypertension,
cardiovascular diseases, diabetes, deep venous thrombosis or thromboembolism did not differ
between the groups.
Table 7. Selected baseline and gynecologic history variables of the study population
______________________________________________________________________
Characteristic Cases n=198  No. (%) Controls n=396  No. (%)
______________________________________________________________________
Age (years) 31.3±5.8 30.5±5.4
   <20 8 (4.0) 11 (2.8)
   >35 50 (25.3) 66 (16.7)*
Lower occupational level 132 (66.7) 228 (57.6)*
Unmarried 84 (42.4) 135 (34.1)*
Parity
   0 84 (42.4) 187 (47.2)
   1-2 89 (44.9) 188 (47.5)
   3 25 (12.6) 21 (5.3)*
Body mass index (kg/m²) 23.0±4.6 23.1±4.4
   <19 17 (8.6) 33 (8.3)
   >25 43 (21.7) 85 (21.5)
Smoker 54 (27.3) 63 (15.9)*
Uterine malformation 9 (4.5) 2 (0.5)*
Spontaneous abortion 58 (29.3) 81 (20.5)*
Induced abortion 35 (17.7) 66 (16.7)




A total of 114 of the case women and 209 of the control women had delivered before (Table 8).
Regarding the course of previous pregnancies, only history of cesarean section (when not
performed because of placental abruption) (OR 1.9; 95% CI 1.2, 3.0) and history of placental
abruption (OR 7.0; 95% CI 1.9, 26) were more common in the abruption group than in the
control group by univariate analysis (Table 8). IUGR and preterm labor (when not related to
earlier placental abruption) were equally common in both groups.
Table 8. Selected obstetric history variables of the parous women
_____________________________________________________________________
Variable Cases n=114  No. (%) Controls n=209  No. (%)
_____________________________________________________________________
Postpartum curettage 4 (3.5) 5 (2.4)
Cesarean section** 40 (35.1) 47 (22.5)*
Placenta previa 1 (0.9) 1 (0.5)
Preeclampsia or PIH 21 (18.4) 27 (12.9)
IUGR** 13 (11.4) 16 (7.7)
Intrauterine fetal death 5 (4.4) 5 (2.4)
Preterm labor <37 wk** 14 (12.3) 15 (7.2)
Placental abruption 10 (8.8) 3 (1.4)*
____________________________________________________________________________________________
*p<0.05
** Cases with history of previous placental abruption were excluded.
PIH, pregnancy induced hypertension; IUGR, intrauterine growth restriction
Table 9. Multivariate analysis of the risk factors for placental abruption
_____________________________________________________________________
Variable Adjusted OR (95% CI)             p-value
_____________________________________________________________________
Age >35 years 1.4 (0.9, 2.3) 0.1
Lower occupational level 1.3 (0.9, 1.9) 0.2
Unmarried 1.2 (0.8, 1.8) 0.3
Parity 3 1.6 (0.8, 3.1) 0.2
Smoking 1.7 (1.1, 2.7) 0.03
Uterine malformation 8.1 (1.7, 40.0) 0.003
Spontaneous abortion 1.4 (0.9, 2.1) 0.2
Previous cesarean section** 1.7 (1.1, 2.8) 0.03
Previous placental abruption 4.5 (1.1, 18.0) 0.02
__________________________________________________________________________________________
** Cases with history of previous placental abruption were excluded.
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Multivariate logistic regression analysis was performed by including all variables associated
with placental abruption by univariate analysis (Table 9). In the adjusted analysis, smoking (OR
1.7; 95% CI 1.1, 2.7), uterine malformations (OR 8.1; 95% CI 1.7, 40), history of cesarean
section (for reasons other than abruption) (OR 1.7; 95% CI 1.1, 2.8), and history of placental
abruption (OR 4.5; 95% CI 1.1, 18) remained significant independent risk factors for placental
abruption.
Clinical presentation and risk factors for placental abruption during the pregnancy (II)
Placental abruption was classified as total in 13 cases (7%) and partial in 185 cases (93%).
Overall, 117 (59%) of the case women delivered preterm, compared to 40 (10%) of the control
women (OR 12.9, 95% CI 8.3, 19.8). Of the case women, 180 (91%) delivered by cesarean
section compared to 95 (24%) of the control women (OR 34.7, 95% CI 20.0, 60.1). Of the
newborns with placental abruption, 51 (25%) were growth restricted compared to 16 (4%) of the
control babies (OR 7.9, 95% CI 4.4, 14.3). Ten infants (4.8%) died in utero, as compared with 2
infants (0.5%) in the control group. The perinatal mortality rate was 9.2% (19 of 207), as
compared with 1% (4 of 404) in the control group (OR 10.1, 95% CI 3.4, 30.1).
Univariate analyses showed that compared to the controls, the case women (OR 2.1, 95% CI 1.4,
3.3) and their partners (OR 2.3, 95% CI 1.4, 3.6) more often were smokers through the
pregnancy. If both partners were smokers the risk for placental abruption was 4.8-fold (95% CI
2.2, 10.0). After antenatal clinic counseling, only 11% of the smoking women stopped smoking
during pregnancy.
Case women used alcohol more often (OR 2.6, 95% CI 1.3, 5.0). Other risk factors associated
with placental abruption were vaginal bleeding during the second (OR 2.4, 95% CI 1.3, 4.4) or
third trimester (OR 2.5, 95% CI 1.1, 5.6), placenta praevia (OR 6.2, 95% CI 1.7, 23.3),
preeclampsia (OR 2.7, 95% CI 1.3, 5.4), and chorioamnionitis (OR 3.3, 95% CI 1.1, 10.2) (Table
10 and 11).
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Table 10. Selected characteristics related to the course of the index pregnancy
______________________________________________________________________
Variable Cases n=198  No. (%) Controls n=396 No. (%)
______________________________________________________________________
Assisted conception 13 (6.6) 24 (6.1)
Behavioral
  Smoking by
      Woman ** 50 (25.3) 54 (13.6)*
      Partner 40 (20.2) 40 (10.1)*
      Both 22 (11.1) 10 (2.5)*
  Alcohol consumption 20 (11.0) 18 (4.6)*
Pregnancy complications
Bleeding I trimester 16 (8.1) 22 (5.6)
  Bleeding II trimester 22 (11.1) 20 (5.1)*
  Bleeding III trimester 13 (6.6) 11 (2.8)*
  Placenta previa 9 (4.5) 3 (0.8)*
  Chronic hypertension 9 (4.5) 19 (4.8)
  PIH 18 (9.1) 22 (5.6)
  Preeclampsia 19 (9.6) 15 (3.8)*
  Maternal diabetes
      Type I or II 2 (1.0) 6 (1.5)
      Gestational 18 (9.1) 43 (10.9)
  Prolonged PPROM 10 (5.1) 10 (2.5)
  Chorioamnionitis 8 (4.0) 5 (1.3)*
  Twin pregnancy 9 (4.5) 8 (2.0)
_____________________________________________________________________________________________
*p<0.05
**Both groups include 11 single mothers
PIH, pregnancy induced hypertension; PPROM, preterm premature rupture of the membranes
Table 11. Multivariate analysis of the risk factors for placental abruption
______________________________________________________________________
Variable Adjusted OR (95% CI)
______________________________________________________________________
Maternal smoking 1.8 (1.1, 2.9)
Paternal smoking 2.2 (1.3, 3.6)
Use of alcohol 2.2 (1.1, 4.4)
Bleeding in II or III trimesters 1.7 (0.9, 3.0)
Placenta previa 5.7 (1.4, 23.1)
Preeclampsia 2.7 (1.3, 5.6)
Chorioamnionitis 3.3 (1.0, 10.0)
_____________________________________________________________________________________________
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A multivariate logistic regression analysis was performed of all variables associated with
placental abruption by univariate analyses. In the adjusted analyses, maternal smoking (OR 1.8;
95% CI 1.1, 2.9), paternal smoking (OR 2.2; 95% CI 1.3, 3.6), use of alcohol (OR 2.2; 95% CI
1.1, 4.4), placenta previa (OR 5.7; 95% CI 1.4, 23.1), preeclampsia (OR 2.7; 95% CI 1.3, 5.6),
and chorioamnionitis (OR 3.3; 95% CI 1.0, 10.0) remained independently associated with
placental abruption (Table 11).
The clinical manifestations of placental abruption are shown in Table 12 and Figure 3. Placental
abruption occurred before labor in 146 (74%) cases and during labor in 52 (26%) cases. Vaginal
bleeding was present in 138 (70%), abdominal pain, uterine tenderness, uterine tetanic
contractions or hypertonic uterus in 100 (51%) cases, and bloody amniotic fluid in 93 (50%)
cases. Fetal heart rate abnormalities (bradycardia, repetitive late decelerations, or decreased beat-
to-beat variability) were present in 137 (69%) cases. Retroplacental blood clot was seen by
ultrasound in 30 (15%) cases. Decreased fetal movements were reported in 22 (11%) cases.
Seventy nine percent of the infants were born within 24 hours after the first symptoms of
placental abruption, and 24% were born in less than one hour.
Table 12. Clinical manifestations of placental abruption
______________________________________________________________________
Characteristic N=198  No. (%)
______________________________________________________________________
Placental abruption detected
   During labor 52 (26)
   Before labor 146 (74)
Vaginal bleeding 138 (70)
Abdominal pain, uterine tenderness, uterine tetanic 100 (51)
   contractions, or hypertonic uterus
Bloody amniotic fluid 93 (50)
Fetal heart rate abnormalities 137 (69)
Retroplacental blood clot by ultrasound 30 (15)
Decreased fetal movements 22 (11)
Onset of symptoms before delivery
   <1 h 47 (24)
   1-24 h 108 (55)
   >24 h 22 (11)
   Unknown 21 (11)
Extent of abruption
   Total 13 (7)
   Partial 185 (93)
_____________________________________________________________________________________________
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Figure 3. Pain and vaginal bleeding as symptoms of placental abruption
Alpha-fetoprotein and free beta-human chorionic gonadotrophin in prediction of placental
abruption (III)
Median of the MSAFP MoM was significantly higher (p=0.004) in the abruption group (median
1.21, interquartile range [IQR] 1.00-1.52) compared to that in the control group (median 1.07,
IQR 0.83-1.29) when adjusted for gestational age and maternal weight (Figure 4). MSAFP levels
of   1.5 MoM were  more common among cases (15 women, 26%) than among controls (9
women, 8%) (odds ratio [OR] 3.9; 95% confidence interval [CI] 1.6-9.7). In contrast, median of















Figure 4. Second trimester maternal serum alpha-fetoprotein concentrations (serum AFP
multiples of median [MoM] in patients with placental abruption and in controls. (y-axis:
logarithmic scale). Horizontal lines indicate the median of MSAFP MoM values.
A multivariate logistic regression analysis was performed by including into the model all
variables with p-value  0.2 in the univariate analysis (Table 13). In the adjusted analysis
MSAFP  1.5 MoM (OR 4.5; 95% CI 1.7-11.9) remained as a significant independent risk factor
for placental abruption (Table 13).
Table 13. Multivariate analysis of the risk factors for placental abruption
______________________________________________________________________
Variable Adjusted OR (95% CI) p-value
______________________________________________________________________
MSAFP 1.5 MoM 4.5 (1.7, 11.9) 0.003
Parity 3 0.9 (0.1, 5.9) 0.9
Smoker 3.2 (1.3, 7.7) 0.009
Previous placental abruption 3.2 (0.4, 24.9) 0.26
Preeclampsia 4.8 (0.8, 29.9) 0.09
Bleeding in II/III trimester 4.8 (1.4, 16.5) 0.01
Placenta previa 9.1 (0.8, 101.9) 0.07
_____________________________________________________________________________________________
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A cutoff value of MSAFP which would best discriminate between the cases and the controls was
attempted to define. However, using ROC curve analysis it was unable to identify any useful
cutoff value suitable for screening. For example, the cutoff   1.5 MoM showed a sensitivity of
only 29% with 10% false positive rate and cutoff  2.0 MoM showed a sensitivity of only 11%
with 2% false positive rate (Figure 5).
Figure 5. Receiver operating characteristic (ROC) curve showing the sensitivity and false-
positive rate (1-specificity) of second trimester maternal serum alpha-fetoprotein (MSAFP)
concentrations in predicting placental abruption.  The numbers on the curve denote various
cutoff points of MSAFP.
Angiogenic factors in prediction of placental abruption (IV)
The levels of sEng ranged from 3.0 to 13.1 ng/ml in cases and from 3.3 to 15.2 ng/ml in controls.
Their medians (5.1 ng/ml vs. 5.5 ng/ml) or interquartile ranges (IQR 4.0-6.6 ng/ml vs. 4.4-6.6
ng/ml) showed no difference between the groups (p=0.3) (Figure 6).
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Figure 6. Serum levels of soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt-1),
placental growth factor (PlGF) and sFlt-1/PlGF ratio at gestational weeks 15 to 16 in women
with placental abruption and in control women
The levels of sEng were not related to the time from serum sampling to the abruption (14-26
weeks) (r=0.06; p=0.7). Parous women with abruption had lower sEng levels than parous
controls [median 4.6 (IQR 3.5-5.4) vs. 5.4 (IQR 4.5-7.0), p<0.05]. Moreover, the levels of sEng
in hypertensive women with abruption were not different from those in normotensive women.
Neither depended the levels of sEng on the maternal age nor subsequent development of SGA in
either group (data not shown). Within cases, smoking women had lower sEng levels than non-
smoking women [median 4.3 (IQR 3.5-5.1) vs. 5.6 (IQR 4.9-7.1), p<0.05], and parous women
had lower sEng levels than nulliparous women [median 4.6 [IQR 3.5-5.4) vs. 5.7 (IQR 4.7-7.5),
p<0.05].  Within controls, women with smaller body mass index (  22) had higher sEng levels
than women with higher body mass index (>22) [median 6.0 (IQR 5.0-7.0) vs. 4.8 (IQR 4.2-5.8),
p<0.05].
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The levels of sFlt-1 [median 743.0 pg/ml (IQR 606.7-942.7 pg/ml) vs. 792.9 pg/ml (IQR 605.9-
1053.6 pg/ml), p=0.6] or PlGF [median 82.8 pg/ml (IQR 58.6-99.8 pg/ml) vs. 80.3 (IQR 58.0-
93.3), p=0.7] showed no difference between the study groups (Figure 1). The levels of sEng
correlated negatively with the levels of PlGF (r=-0.31; p=0.048) and positively to the sFlt-
1/PlGF ratios (r=0.73; p<0.001) in the abruption group. In the control group sEng was not
related to PlGF but it correlated positively with sFlt-1 (r=0.38; p=0.007) and sFlt-1/PlGF ratio
(r=0.34; p=0.02).
C-reactive protein and chlamydial antibodies in placental abruption (V)
There was no difference in the CRP levels between the cases and the controls (median 2.35 mg/l
[IQR 1.09-5.93 ] vs. 2.28 mg/l [IQR 0.92-5.01], NS). As expected, the CRP levels were higher in
obese women (body mass index [BMI] >25) both in the abruption and in the control group
(median 6.82 mg/l [IQR 3.25-9.65] vs. 4.98 mg/l [IQR 1.25-9.77], NS) compared to lean women
(BMI<19) (median 2.18 mg/l, [IQR 1.04-4.73] vs. 1.45 mg/l [IQR 0.32-5.25], NS) or women
with normal BMI (median 1.95 mg/l [IQR 0.87-4.44] vs. 2.10 mg/l [IQR 0.86-4.24], NS) (Figure
7), but there was no difference between the study groups. The CRP levels were then compared in
the abruption group between the smoking and the non-smoking cases, cases with or without
preterm birth, preeclampsia or IUGR newborn. No differences were found in the CRP levels
between these groups (data not shown). The estimated risk of placental abruption in relation to
elevated CRP (upper quartile, >5.4 mg/l, OR 1.3; 95% CI 0.9-2.1) remained unchanged after
adjusting for age and smoking (OR 1.3; 95% CI 0.9-2.1).
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Figure 7. CRP levels in women with subsequent placental abruption (grey bars) and in women
with normal pregnancy (white bars) by BMI
C. pneumoniae specific IgG and IgA antibodies and C. trachomatis specific IgG and IgA as well
as CHSP60 specific IgG antibody prevalence rates were similar in both groups (Table 14).
Similarly, CRP levels did not differ in relation to chlamydial antibodies (data not shown).
Table 14. CRP levels and antibody prevalence rates to C. trachomatis, CHSP60 or to C.
pneumoniae in the cases and controls
______________________________________________________________________
Variable Cases n=181  No. (%) Controls n=261  No. (%) p-value
______________________________________________________________________
CRP median (IQR) 2.35 (1.09-5.93) 2.28 (0.92-5.01) NS
C. trachomatis IgG 27 (14.9) 36 (13.8) NS
C. trachomatis IgA 8 (4.4) 7 (2.7) NS
CHSP60 29 (16.0) 40 (15.4) NS
C. pneumoniae IgG 98 (54.1) 146 (55.6) NS




Significant progress in perinatal medicine has taken place during the last few decades. This
includes e.g. sophisticated ultrasound equipments and delicate methods to assess fetal
oxygenation and other wellbeing, and for a good reason we can say that a fetus has become a
patient for perinatologists. As a result, perinatal mortality and morbidity have dramatically
decreased in the Western world (Konje and Taylor. 2001). It is unfortunate that this favorable
development hardly concerns placental abruption. Although maternal and perinatal mortality
rates have decreased, placental abruption still manifests itself almost similarly as in 1775 when
first described by Edward Rigby (Rigby. 1775, Eskes. 1997) and the impact of this complication
on other perinatal outcome is much larger than approximated from its rate. Therefore new data
are needed on placental abruption and this was the purpose of the present study.
In this study the rate of placental abruption (0.42%) was twice as high as that (0.21%) reported
from another university hospital during 1962-1981 in Finland (Ylä-Outinen et al. 1987). This
suggests that the rate of placental abruption may have increased. An increase has also been
reported from other countries (Saftlas et al. 1991, Rasmussen et al. 1996). However, our rate of
placental abruption is lower than reported from elsewhere (0.5-0.6%) (Ananth et al. 1999a,
Ananth et al. 1999b, Baumann et al. 2000, Ananth and Wilcox. 2001, Kyrklund-Blomberg et al.
2001, Toivonen et al. 2002) but higher than in a recent large Norwegian study (0.38 %) (Nilsen
et al. 2008). The prevalence of placental abruption seems to be lower in the Nordic countries
than in the U.S. This could reflect differences in diagnostic criteria, different study populations,
or different recording of placental abruption. For instance, in many studies the lowest gestational
age considered has not been defined or mentioned (Kåregård and Gennser. 1986, Saftlas et al.
1991, Rasmussen et al. 1996, Ananth et al. 1999b, Kyrklund-Blomberg et al. 2001). Also, in our
study small abruptions may not have been recorded in hospital charts or may have been recorded
under different diagnoses. However, it is unlikely that this bias may have changed the key
findings of our study.
Risk factors associated with placental abruption
Although univariate analysis identified many risk factors, only smoking, uterine malformation,
previous cesarean section and history of placental abruption were significantly associated with
the increased risk of placental abruption in a subsequent pregnancy. During the index pregnancy
independent risk factors for placental abruption were maternal and paternal smoking, use of
alcohol, placenta previa, preeclampsia, and chorioamnionitis.
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Smoking was the strongest risk factor for placental abruption. A meta-analysis showed that
smoking increases the risk of placental abruption by 90% and 15-25% of episodes could be
prevented if women stopped smoking during pregnancy (Ananth et al. 1999a). In our series
maternal smoking doubled the risk of placental abruption. An interesting new finding was that
also paternal smoking was an independent risk factor irrespective of whether the women
smoked. This can be explained by passive exposure of the pregnant woman to partner’s smoking,
or that women whose partners smoked also smoked despite claiming of being nonsmokers. A
Finnish study based on cotinine assessment suggests that about one out of four smoking
parturients deny smoking (Bardy et al. 1993). Smoking by both partners, which increased the
risk nearly 5-fold, may reflect a more liberal attitude towards smoking in the family. The
mechanisms explaining the association between smoking and placental abruption may include
decidual necrosis at the margins of the placenta, placental microinfarcts, atheromatous or
fibrinoid changes, or the development of hypovascular and atrophic placental villi (Naeye. 1980,
Andres and Day. 2000). Increased capillary fragility may result in arterial rupture leading to
placental abruption (Kaminsky et al. 2007). Although women who stop smoking early in
pregnancy have similar risk of abruption than nonsmoking women (Naeye. 1980, Ananth and
Cnattingius. 2007), smoking cessation during pregnancy is problematic. In one study, smoking
discontinuation rate was 18% (Lumley. 1987). In our study only 7% of smoking women with
subsequent abruption and 14% of smoking control women were able to stop smoking during
pregnancy. Most of the studies are based on self-reported smoking behavior (Ananth et al.
1999a). Social stigma associated with smoking may lead to underreporting. Studies using
biochemical markers such as cotinine assessment, the primary metabolite of nicotine, suggest
that women consistently underreport smoking behavior (Bardy et al. 1993, Moore et al. 2002).
Clearly, stopping smoking is the best intervention to reduce perinatal mortality and morbidity
(Pfarrer et al. 1999).
Uterine anomalies, caused by abnormal fusion of the Müllerian ducts (Heinonen et al. 2000), are
found in 0.1-2% of all women (Acien. 1997). We found an association between placental
abruption and congenital malformations of the uterus. Although mentioned in some old
textbooks (Green. 1989), none of the most recent studies have confirmed this association. In our
study women with uterine malformation had 8-fold risk for placental abruption. Uterine
malformation may lead to poor decidualization and placentation. Also the contractility of
malformed uterus may be disturbed or uncoordinated increasing the risk for preterm separation
of the placenta (Dabirashrafi et al. 1995) . However, it is possible that in our study malformed
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uterus may have been more readily diagnosed among cases who underwent cesarean deliveries
or had increased rate of spontaneous abortions, resulting in reporting bias.
Past cesarean section increases the risk of placental abruption by approximately 40% and short
interpregnancy interval after cesarean section further increases this risk (Hemminki and
Meriläinen. 1996, Rasmussen et al. 1999, Getahun et al. 2006, Yang et al. 2007). In our study,
the risk of placental abruption associated with history of cesarean section was almost twofold. It
is likely that uterine low segment scar may impair placental attachment and perfusion in
anteriorly located placentas, and therefore an increase in the risk of abruption is seen
(Rasmussen et al. 1999, Lydon-Rochelle et al. 2001). Also, ligation of uterine vessels at the time
of cesarean section may furher damage endometrial and myometrial lining. Not surprisingly,
history of cesarean section also increases the risk of stillbirth and placenta previa in subsequent
pregnancies (Smith et al. 2003, Getahun et al. 2006, Yang et al. 2007).
The recurrence rate of placental abruption was 8.8 % in our study, which is in line with previous
studies (Kåregård and Gennser. 1986, Rasmussen et al. 1997, Konje and Taylor. 2001). It is not
known why placental abruption recurs in some women. Recurrence cannot be only explained by
the common risk factors (Ananth and Cnattingius. 2007). Placental abruption may simply cause
a permanent damage to the endometrium which then increases the risk of inappropriate
placentation in subsequent pregnancy (Ananth et al. 1996). Genetic predisposition or
immunological factors may also play a role. Thus, a history of placental abruption should alert of
an increased risk of subsequent placental abruption. Testing placental function and assessment of
fetal growth six weeks before the time of previous placental abruption has been advocated in
order to lower the risk for recurrent placental abruption (Rasmussen et al. 2001).
Alcohol use doubled the risk for placental abruption in our study, and this is in line with some
(Kaminski et al. 1976, Halmesmäki. 1988, Burd et al. 2007), but not all studies (Kramer et al.
1997). Alcohol easily crosses placenta and accumulates in the fetus and amniotic fluid (Burd et
al. 2007).  Alcohol use during pregnancy is a known risk factor for fetal neurodevelopmental
abnormalities and fetal malformations (Kaminski et al. 1976, Sokol et al. 2003). Alcohol
exposure also causes vasoconstriction in the placenta and umbilical cord and disturbs the feto-
maternal hormonal balance (Gabriel et al. 1998, Burd et al. 2007) which may contribute to the
risk of abruption. Villus infarction and intervillous thrombosis are more common in placentas of
alcohol users (Burd et al. 2007). In alcohol-exposed pregnancies both placental and fetal growth
is impaired. Alcohol usage also causes intrapartum asphyxia and may lead to stillbirth (Burd et
al. 2007).
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Bleeding during second or third trimester and placenta previa were also risk factors for placental
abruption. This is in accordance with previous studies (Kramer et al. 1997, Baumann et al. 2000,
Kyrklund-Blomberg et al. 2001). The presence of a retroplacental hematoma in the first trimester
is known to increase the risk for subsequent placental abruption (Sipilä et al. 1992, Nagy et al.
2003). Vaginal bleeding after 28 weeks also predicted placental abruption, as has been shown
before (Baron and Hill. 1998). However, in our study bleeding in the second trimester or the
third trimester was not an independent risk factor in the adjusted analyses which can be
explained by the strong impact of placenta previa on placental abruption. According to the
literature 10% of women with placenta previa have a coexisting abruption (Konje and Taylor.
2001), although in some studies these cases are not considered abruptions (Oyelese and Ananth.
2006).
Preeclampsia and chorioamnionitis were strong risk factors for placental abruption.
Preeclampsia was associated with a 2.7-fold risk of placental abruption, while chronic
hypertension or PIH was not. This is in line with previous studies (Ananth et al. 1997, Kramer et
al. 1997). Preterm PROM has been associated with the risk of placental abruption (Ananth et al.
1996, Toivonen et al. 2002), which may be a consequence of ascending intrauterine infection.
Another study showed that prolonged preterm PROM increased the risk of abruption even more
(Ananth et al. 2004). However, this was not seen in our study. This may be due to the liberal use
of prophylactic antibiotics which may prevent chorioamnionitis or to our active policy of
inducing labor within 12-24 hours after preterm PROM if the duration of gestation exceeds 34
weeks. Nevertheless, chorioamnionitis increased the risk for placental abruption more than 3-
fold.
Assisted conception, polyhydramnion, oligohydramnion, maternal diabetes, uterine trauma,
external cephalic version, short umbilical cord, and coagulation defects  have all been associated
with  placental abruption. None of these risk factors was associated with placental abruption in
our study which may be due to small numbers. Also, our cases were not systematically tested for
thrombophilic disorders. In some (Ananth et al. 2003, Campbell and Templeton. 2004) but not
all studies (Kramer et al. 1997) multiple pregnancy has been a risk factor for placental abruption.
This was not found in our study. Many of these additional risk factors were infrequent in our




The clinical manifestations of placental abruption can be highly variable. Vaginal bleeding was
the most common symptom (70%) of placental abruption, and pain was present in half of the
cases. This is in line with previous reports (Konje and Taylor. 2001). However, it is remarkable
that nearly one out of five cases had neither pain nor bleeding. Yet, of these women nearly all
presented with CTG changes. Only two women had retroplacental hematoma as the only sign,
and both newborns were growth restricted. According to the literature up to 50% of abruptions
take place during labor (Baron and Hill. 1998), but this was the case in only 27% of our patients.
The liberal use of ultrasound examination and cesarean section at an early phase in patients
suspected of having abruption may have contributed to this difference. More than 90% of our
cases with abruption were delivered by cesarean section. This rate is much higher than in most
previous studies (Kåregård and Gennser. 1986, Toivonen et al. 2002). Clear retroplacental blood
clot before delivery was detected by ultrasound in only 15% of our cases. Therefore, the absence
of ultrasound findings should not preclude the diagnosis. Ultrasound is not a sensitive method of
diagnosing placental abruption but it is useful diagnosing coincident placenta previa (Konje and
Taylor. 2001). Prematurity and intrauterine growth restriction are major problems associated
with placental abruption (Ananth et al. 1999b); 59% of the case women had a preterm birth and
25% of the newborns were growth restricted. Also, perinatal mortality was increased 9-fold.
Biochemical markers
Several biochemical markers have been studied in order to predict placental abruption but none
have emerged clinically useful (Nolan et al. 1993, Bartha et al. 1997, Chandra et al. 2003, Florio
et al. 2003, Dugoff et al. 2005, Signore et al. 2006). Preeclampsia and placental abruption share
similar placental histopathology and also insufficient uteroplacental circulation (Steinborn et al.
2004, Oyelese and Ananth. 2006). Elevated second-trimester AFP levels or -hCG levels, and
elevated sEng or sFlt-1 and decreased PlGF levels have been demonstrated in preeclampsia (Liu
et al. 1999, van Rijn et al. 1999, Chandra et al. 2003, Dugoff et al. 2005) but not much is known
of these markers in placental abruption. Generalized inflammatory response and endothelial cell
dysfunction have also been demonstrated in preeclampsia (Bowen et al. 2001, Redman and
Sargent. 2005, Ness and Sibai. 2006). In one study, CRP levels were increased in women with
subsequent preeclampsia (Qiu et al. 2004a). C. pneumoniae has been linked to preeclampsia
(Heine et al. 2003, Goulis et al. 2005). C. trachomatis has been linked to several adverse
pregnancy outcomes (McGregor and French. 1991, Claman et al. 1995, Gencay et al. 2000,
Karinen et al. 2005). Although there is some evidence that chronic inflammation is implicated in
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placental abruption (Ananth et al 2006) none of these markers have been studied in placental
abruption.
Elevated second-trimester MSAFP-levels or MS -hCG-levels have been linked to many
pregnancy complications but placental abruption has only represented one of many (Katz et al.
1990, Purdie et al. 1983, Liu et al. 1999, van Rijn et al. 1999, Chandra et al. 2003). After
exclusion of pregnancies with fetal chromosomal or structural abnormalities, the MSAFP or the
MS -hCG cutoff level most often used for adverse perinatal outcome has been 2 or 2.5 MoM
(van Rijn et al. 1999, Chandra et al. 2003, Dugoff et al. 2005). In our study the goal was to find
out whether MSAFP or MS -hCG levels could specifically predict placental abruption.
Fetal liver produces AFP. Due to renal output, AFP accumulates in amniotic fluid especially
during the second trimester. From amniotic fluid, AFP enters maternal circulation
transplacentally (70%) and, to some extent, transamniotically (Kraus et al. 2004). Placental
abruption may often be a consequence of spiral artery rupture, causing retroplacental hematoma
and then placental detachment (Haddow and Palomäki. 1999). Disruption in the feto-maternal
interface in early second trimester might permit transfer of AFP into maternal circulation
(Chandra et al. 2003). This blood, rich in AFP, could be responsible for elevation in MSAFP in
our patients with subsequent placental abruption since the median of MSAFP was higher in
women who developed placental abruption. After adjusting for potential confounding factors,
MSAFP 1.5 MoM remained an independent predictor for placental abruption. However, the
clinical usefulness of this test was limited due to low sensitivity and high false-positive rate. -
hCG levels did not predict placental abruption in our study.
Although the etiology of placental abruption is unknown the trophoplastic invasion in the spiral
arteries and consequent early vascularization may be defective (Dommisse and Tiltman. 1992,
Kraus et al. 2004). Therefore, it is possible that an imbalance between placental proangiogenic
and antiangiogenic factors locally in the placenta or in maternal blood precedes placental
abruption. In one study the serum levels of PlGF were decreased and the ratios of sFlt-1/PlGF
were increased in nulliparous women several weeks before placental abruption, but this was the
case only in women who also developed preeclampsia (Signore et al. 2006). Our data based on
serum samples collected at the time of critical remodelling of the spiral arteries failed to identify
women with subsequent placental abruption which is in agreement with the previous study
(Signore et al. 2006). These results strongly imply that circulating proangiogenic PlGF and
antiangiogenic sFlt-1 in early or midgestation do not predict placental abruption.
Endoglin, a cell membrane coreceptor for different growth factors, is produced in endothelium
and syncytiotrophoblasts and acts as an important antiangiogenic factor (Venkatesha et al. 2006).
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In the genetically manipulated mice the overproduction of this factor leads to insufficient general
and placental angiogenesis (Li et al. 1999). The soluble form of endoglin leaking into maternal
blood was markedly increased in early second trimester in women who later become
preeclamptic (Levine et al. 2006). We found that the levels of sEng were normal 14-26 weeks
before placental abruption. Thus, in this regard sEng behaved like sFlt-1, PlGF, or their ratio. We
could not demonstrate any elevation in sEng even in women who later became hypertensive,
with or without placental abruption. This can well be due to the small number of hypertensive
women included in our study. Another study showed significantly elevated levels of sEng
already at 17-20 gestational weeks in women with subsequent early preeclampsia (Levine et al.
2006).
Maternal smoking has been associated with reduced levels of sEng and sFlt-1 and increased
levels of PlGF (Levine et al. 2006). We found that sEng levels were significantly lower in
smoking women with abruption. This effect might be part of adaptive angiogenesis which means
increased placental weight and impaired placental function among smoking women (Pfarrer et
al. 1999).
Immunological defects may also play a role in the etiology of placental abruption (Matthiesen et
al. 1995, Steinborn et al. 2003b) leading to excessive maternal inflammatory response with
increased release of cytokines which results in a chain of events including shallow trophoblast
invasion, defective spiral artery remodelling, placental infarctions and thrombosis (Matthiesen et
al. 2005). Excessive activation of the immune system may suggest past exposure to major
antigens (Steinborn et al. 2004). Chlamydiae are common pathogens and immune system
modulators (Paavonen and Eggert-Kruse. 1999, Hammerschlag. 2007, Meyers et al. 2007). CRP
is a sensitive marker of inflammation, and Chlamydiae can induce such an inflammation. Thus,
evaluating these biomarkers in the prediction of placental abruption was meaningful.
CRP is a protein synthesized in hepatocytes. Elevated CRP values reflect the amount of
circulating inflammatory cytokines and inflammation in general (Loukovaara et al. 2003, Qiu et
al. 2004a). Highly sensitive CRP predicts subsequent coronary heart disease events (Danesh et
al. 2004). The risk of premature cardiovascular disease is increased after maternal placental
disease syndrome, i.e. hypertensive disorders, placental abruption or infarction (Ray et al. 2005).
CRP concentrations correlate with BMI (Qiu et al. 2004a). We could also demonstrate the effect
of BMI on CRP levels but as such CRP alone did not predict placental abruption. This implies
that increased CRP levels in early pregnancy do not contribute to the pathogenesis of placental
abruption. However, we cannot exclude the possibility that CRP levels increase later in
gestation.
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Many adults have been exposed to C. pneumoniae (Goulis et al. 2005). C. pneumoniae
antibodies have been increased in women with preeclampsia in some (Heine et al. 2003, Goulis
et al. 2005), but not all studies (Teran et al. 2003, Raynor et al. 2004). In preeclampsia as well as
in placental abruption a common histological finding in spiral arteries is atherosis, a lesion
involving same lipid-laden foam cells also observed in atherosclerosis (Goulis et al. 2005,
Ananth et al. 2006b). C. pneumoniae infection has been linked to atherosclerosis and coronary
artery disease (Leinonen and Saikku. 2002). This organism has also been detected in
atherosclerotic artery tissue (Leinonen and Saikku. 2002). It has been proposed that C.
pneumoniae causes chronic inflammation, which can result in clinical disease syndromes
developing years after the primary infection (Goulis et al. 2005). However, we could not
demonstrate any association between C. pneumoniae antibodies and placental abruption.
C. trachomatis is the most common cause of bacterial sexually transmitted infections. More than
10% of women of reproductive age report a history of C. trachomatis infection (Gencay et al.
2000). C. trachomatis infection has been linked to an increased incidence of pregnancy loss, low
birth weight, prematurity, preterm labor and premature rupture of the membranes (McGregor and
French. 1991, Claman et al. 1995, Gencay et al. 2000, Blas et al. 2007). C. trachomatis IgG
seropositivity indicates past, persistent or latent C. trachomatis infection and has also been
detected more often in the sera of mothers with stillbirth (Gencay et al. 2000). One recent study
suggested that chronic C. trachomatis infection may lead to systemic low-grade inflammation
and elevated CRP levels contributing to the pathogenesis of preterm delivery (Karinen et al.
2005). C. trachomatis is a small intracellular, gram-negative bacterial organism. Such
intracellular organisms can escape humorally mediated host defences, which may account for the
typically low antibody levels in uncomplicated infection and the prolonged persistence of
untreated infection (McGregor and French. 1991). Heat shock proteins (HSPs) protect cells
against different forms of stress, such as hypoxia, ischemia and hyperoxia (Di Felice et al. 2005).
Chlamydial heat shock proteins have been linked to the development of immunopathological
damage after C. trachomatis infection (Karinen et al. 2005, Meyers et al. 2007). Serum
antibodies to chlamydial HSPs have been associated with poor reproductive outcome and also to
the development of cervical or ovarian cancer (Claman et al. 1995, Koskela et al. 2000, Anttila et
al. 2001, Paavonen et al. 2003, Di Felice et al. 2005, Karinen et al. 2005). However, we failed to
demonstrate any association between Chlamydiae and placental abruption. An excessive
activation of the immune system seen in placental abruption may suggest past exposure to major
microbial antigens (Steinborn et al. 2004) other than Chlamydiae.
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Multiple risk factors for placental abruption exist, but the numbers of cases in our study were too
small to test all risk factors. Also, we were unable to substantiate the association between
placental abruption and coagulation abnormalities since our cases were not systematically tested
for thrombophilic disorders. The limitations concerning biochemical markers were that test
results from all women were not available since the blood samples had been drawn outside our
hospital district. Also, for analysing angiogenic factors only early second trimester serum
samples were available and only first trimester serum samples for the analysis of CRP analyses.
Thus we cannot exclude the possibility that these markers might have predicted placental
abruption later in pregnancy.
The strengths of our study include systematic data collection and the university hospital setting.
Our university hospital is a tertiary referral hospital that serves one fifth of the Finnish female
population and our department had more than 9,000 deliveries per year during the study period.
Therefore, our data are likely to represent rather well the situation in the whole country. We used
systematic criteria for case definition in order to avoid selection bias. The relatively large
number of cases made it possible to perform multivariate analyses of the risk factors. Also, our
case series was collected at the time when screening and diagnostic ultrasound examinations
were already extensively used in obstetric practice. This allowed us to evaluate whether the
liberal use of ultrasound had any obvious impact on the diagnosis or management of placental
abruption although our study was not a randomized trial. The strength conserning biochemical
marker studies was that the study was population based. The serum samples were obtained prior
to the study which excludes selection bias.
In conclusion, although univariate analysis identified many prepregnancy risk factors for
placental abruption, only smoking, uterine malformation, previous caesarean section and history
of placental abruption remained significant by multivariate analysis. During the index pregnancy
maternal alcohol consumption and smoking and smoking by the partner turned out to be the
major independent risk factors for placental abruption. Smoking by both partners multiplied the
risk. Other independent risk factors were coexisting placenta previa, preeclampsia and
chorioamnionitis. Nearly one fifth of women with placental abruption did not have the classical
symptoms of bleeding and pain. The liberal use of ultrasound examination contributed little to
the management of women with placental abruption. Prematurity and intrauterine growth
restriction were the major problems associated with placental abruption; 59% of the case women
had a preterm birth and 25% of the newborns were growth restricted. Also, perinatal mortality
was increased 9-fold. Although second-trimester MSAFP levels were higher in women with
subsequent placental abruption, clinical usefulness of this test was limited due to low sensitivity
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and high false positive rate. Similarly, angiogenic factors in early second trimester, or CRP
levels, or chlamydial antibodies in the first trimester failed to predict placental abruption.
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CONCLUSIONS
The following conclusions can be drawn:
1.  Placental abruption occurred in 198 of 46 742 parturients (0.42%) in our University
Central  Hospital in 1997-2001. The recurrence rate of placental abruption was 8.8%.
2.  Smoking (OR 1.7), uterine malformation (OR 8.1), previous cesarean section (OR 1.7)
  and history of placental abruption (OR 4.5) were the prepregnancy risk factors associated
  with placental abruption.
3.   The risk factors for placental abruption during the index pregnancy were maternal (OR
  1.8) and paternal (OR 2.2) smoking, alcohol use (OR 2.2), placenta previa (OR 5.4),
  preeclampsia (OR 2.7) and  chorioamnionitis (OR 3.3). Smoking by both parents
  multiplied the risk (OR 4.8).
4.  Vaginal bleeding, abdominal pain, bloody amniotic fluid and fetal heart rate abnormalities
  were the most common clinical signs of placental abruption. Traditional symptoms,
  bleeding and pain, were absent in 19% of the cases. Retroplacental hematoma was seen by
  ultrasound in 15% of  the cases. Of the newborns 25% were small for gestational age, 59%
  were born preterm and 91% were delivered by cesarean section. The perinatal mortality
  rate was 9.2%.
5.   An elevated maternal serum AFP 1.5 MoM was an independent risk factor for placental
  abruption. The clinical usefulness of this test was limited due to low sensitivity (29%) and
  high false positive rate (10%). Maternal serum free beta human chorionic gonadotrophin
  did not  predict placental abruption.
6.   Soluble endoglin, soluble fms-like tyrosine kinase 1 and placental growth factor did not
  predict placental abruption when tested 14 to 26 weeks before abruption.
7.   Chlamydial antibodies and C-reactive protein did not predict placental abruption when
  tested in the first trimester.
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